It is made available under a CC-BY-NC-ND 4.0 International license .

Understanding pediatric long COVID using a tree-based scan statistic approach: An EHR-based cohort study from the RECOVER Program

Corresponding author:

Vitaly Lorman Applied Clinical Research Center Children's Hospital of Philadelphia 2716 South St Philadelphia, PA 19146 Lormanv@chop.edu (267) 428-2845

Authors:

Vitaly Lorman, PhD^{*1}, Hanieh Razzaghi, MPH^{*1}, Suchitra Rao, MBBS, MSCS², Ravi Jhaveri, MD³, Abigail Case, MD⁴, Asuncion Mejias, MD, PhD, MsCS⁵, Nathan M. Pajor, MD, MS⁶, Payal Patel, MD⁷, Deepika Thacker, MD⁸, Seuli Bose-Brill, MD⁹, Jason Block, MD, MPH¹⁰, Patrick C. Hanley, MD, MSHQS¹¹, Priya Prahalad, MD, PhD¹², Yong Chen, PhD¹³, Christopher B. Forrest, MD, PhD¹, L. Charles Bailey, MD, PhD¹, Grace M. Lee, MD, MPH¹⁴

*Co-first authorship

Affiliations:

¹Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA, United States

²Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital of Colorado, Aurora, CO, United States

³Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

⁴Division of Physical Medicine & Rehabilitation, The Children's Hospital of Philadelphia, Philadelphia, PA, United States

⁵Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, United States

⁶Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, United States

⁷Department of Neurology, University of Washington, Seattle, WA, United States

⁸Nemours Cardiac Center, Nemours Childrens Health, Wilmington, DE, United States

It is made available under a CC-BY-NC-ND 4.0 International license .

[°]Internal Medicine and Pediatrics Section, Division of General Internal Medicine, Department of Internal Medicine, Ohio State University College of Medicine and Ohio State University Wexner Medical Center, Columbus, OH, United States

¹⁰Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA, United States

¹¹Division of Endocrinology, Nemours Children's Hospital, Wilmington, DE, United States

¹²Department of Pediatrics, Division of Endocrinology, Stanford University, Stanford, CA, United States

¹³Department of Biostatistics, Epidemiology and Informatics, the University of Pennsylvania, Philadelphia, PA, United States

¹⁴Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States

Keywords: Long COVID, Post-Acute Sequelae of SARS-CoV-2 Infection, COVID-19

Word count: 3854

It is made available under a CC-BY-NC-ND 4.0 International license .

STRUCTURED ABSTRACT

Objectives

Post-acute sequalae of SARS-CoV-2 infection (PASC) is not well defined in pediatrics given its heterogeneity of presentation and severity in this population. The aim of this study is to use novel methods that rely on data mining approaches rather than clinical experience to detect signals associated with PASC.

Materials and Methods

We used a propensity-matched cohort design comparing children identified using the new PASC ICD10CM diagnosis code (U09.9) (N=1250) to children with (N=6250) and without (N=6250) SARS-CoV-2 infection. We used a tree-based scan statistic to identify potential condition clusters co-occurring more frequently in cases than controls.

Results

We found significant enrichment among children with PASC in cardiac, respiratory, neurologic, psychological, endocrine, gastrointestinal, and musculoskeletal systems, the most significant related to circulatory and respiratory such as dyspnea, difficulty breathing, and fatigue and malaise.

Discussion

Our study addresses methodological limitations of prior studies that rely on pre-specified clusters of potential PASC-associated diagnoses driven by clinician experience. Future studies are needed to identify patterns of diagnoses and their associations to derive clinical phenotypes.

Conclusion

We identified multiple conditions and body systems associated with pediatric PASC. Because we rely on a data-driven approach, several new or under-reported conditions and symptoms were detected that warrant further investigation.

It is made available under a CC-BY-NC-ND 4.0 International license .

BACKGROUND AND SIGNIFICANCE

The National Institutions of Health (NIH) launched the new RECOVER initiative in 2021 (1) to leverage electronic health record (EHR) data to better identify and characterize patients with post-acute sequelae of SARS-CoV-2 infection (PASC), defined by the NIH as failure to recover from COVID-19, or those persistently symptomatic for >30 days.(2) In the adult literature, advances have been made to predict PASC among COVID-19 affected patients (3) and to describe etiology, risk factors, and outcomes (4-7). In contrast, there is currently a paucity of rigorous studies that accurately describe PASC in children (8). Research attempting to better elucidate PASC in children has been limited by small sample sizes (9-11), lack of a control group (12-14), or restrictions in source population (15) that limit generalizability to a broader cohort. (17)

Access to EHR data in a large population of children offers an opportunity to better understand the spectrum of PASC across a wide range of demographics and clinical trajectories. A recent exploratory analysis using EHR data to characterize pediatric PASC examined symptoms, diagnoses, and medications occurring more frequently in a large cohort of SARS-CoV-2 viral test-positive patients when compared with SARS-CoV-2-negative controls. Similar studies have also been carried out in adult populations(7). However, these studies are limited in two important ways. First, SARS-CoV-2 positive patients are heterogeneous and therefore analyses are at risk for spurious associations attributable to residual confounding rather than significant clinical findings. Second and relatedly, studies of PASC-associated features employ outcomes defined by clusters of clinically similar diagnosis codes. Clustering clinical codes in this way may bias findings that confirm clinical experience. The rapidly evolving nature of the pandemic and the lack of consensus of specific symptoms that define PASC in children necessitates a more data-driven approach for knowledge discovery.(18)

In this study, we explored syndromic and systemic features associated with a clinical diagnosis of PASC compared to children with and without SARS-CoV-2 infection. The diagnosis code for PASC was established in October 2021 – *U09.9, post COVID-19 condition, unspecified.* Prior to this, the non-specific code, *B94.8, Sequelae of other specified infectious and parasitic diseases,* was proposed as a temporary alternative (19). While these codes reflect clinician judgment in diagnosing patients who may suffer from PASC, they are likely to have a higher positive predictive value than identifying cases using COVID-19- alone. To identify clusters of PASC-associated diagnoses from tens of thousands of diagnosis codes, we used a tree-based scan statistic, a data mining tool which detects signals from hierarchical structures without relying on pre-specifying the clusters of codes of interest. This data-driven technique is especially advantageous in EHR research where mining a large corpus of data is feasible.

MATERIALS AND METHODS

Study Population and Design

The RECOVER PEDSnet EHR population includes EHR data from nine children's hospitals: Children's Hospital of Philadelphia, Cincinnati Children's Hospital Medical Center, Children's Hospital of Colorado, Ann & Robert H. Lurie Children's Hospital of Chicago, Nationwide

It is made available under a CC-BY-NC-ND 4.0 International license .

Children's Hospital, Nemours Children's Health System (in Delaware and Florida), Seattle Children's Hospital, and Stanford Children's Health. The Children's Hospital of Philadelphia's institutional review board designated this study as not human subjects research and the need for consent was waived. The PEDSnet COVID-19 Database Version week 115 was used. This study is part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection (PASC). For more information on RECOVER, visit https://recovercovid.org/.

Our primary analyses focused on two comparisons of interest. Cases consisted of patients with evidence of PASC; the two comparator cohorts were patients with and without SARS-CoV-2 infection. Evidence for PASC comprised a U09.9 diagnosis code, an interface terminology (IMO) term in the EHR with the following strings: ('post' and 'acute' and 'covid') or ('complication' and 'covid'), or a B94.8 diagnosis code. Because the B94.8 code is more general, we did not include such diagnoses where the IMO term indicated something other than PASC. We excluded patients who had a MIS-C diagnosis at any point in time based on the presence of the M35.81, U10, and U10.9 ICD10CM diagnostic codes; therefore, we use 'PASC' to refer specifically to non-MIS-C variants. Patients were considered SARS-COV-2 infected if they had a diagnostic test that was positive for infection (Polymerase Chain Reaction (PCR), antigen, or serology). Serology tests included IgM, IgG anti- N antibodies, IgG anti-S or receptor binding domain (RBD) antibodies, and IgG and IgA undifferentiated antibodies based on criteria from Mejias et al. for positivity due to infection(20). Patients were also considered SARS-COV-2 infected if they had a diagnosis code for COVID-19 in the inpatient or emergency department (ED) setting. We excluded diagnosis codes for COVID-19 in the outpatient setting because of the possibility that the code was assigned as a rule-out diagnosis during a patient evaluation. Further, the observation period in the study aligned with the phase of the pandemic when viral testing was still widely performed in the healthcare setting. Patients were considered SARS-COV-2 uninfected if (1) all available diagnostic tests (PCR, Ag, serology) during the study period were negative and (2) the patient did not have any diagnosis codes indicating SARS-COV-2 infection, MIS-C, or PASC in any setting.

Cohort entry date for incident PASC cases was defined as: (1) the date of the first positive PCR or antigen test, or (2) 4 weeks before the date of the first positive serology test, or (3) 4 weeks before the first occurrence of a diagnosis of PASC if no preceding confirmatory test was available. We recognize that imposing a date of infection may misclassify the risk window between initial infection and PASC diagnosis if no testing data is available but chose to be overly inclusive of patients rather than exclude patients with the diagnosis based on unavailability of testing data. The cohort entry date for non-PASC SARS-CoV-2 infected patients was defined based on the date of the earliest SARS-CoV-2 diagnostic test (unless serology positive, then 4 weeks earlier) or earliest COVID-19 diagnosis/encounter. For SARS-CoV-2 uninfected patients, cohort entry dates were chosen as the date of a random negative test. All patients across case and control definitions were < 21 years of age at the date of cohort entry.

It is made available under a CC-BY-NC-ND 4.0 International license .

Additionally, we conducted a sensitivity analysis in which we compared SARS-CoV-2 positive to SARS-CoV-2 negative patients during the post-acute period—a description of the methods and results of this analysis are included in the supplementary appendix.

Matching

We extracted data for our study from the RECOVER pediatric database by identifying any patient who met study inclusion criteria between March 1, 2020, and June 22, 2022. We used a propensity score matched approach to balance covariates between cases and each of the comparison groups to minimize potential confounding (21). Propensity scores were estimated using logistic regression as the probability of a PASC diagnosis conditional on the following covariates: institution, age group (<1, 1-4, 5-11, 12-15, 16-20 years), sex, race/ethnicity (white non-Hispanic (NH), Black NH, Hispanic, Asian NH, multi-racial NH, other NH), and clinical setting of testing. Additionally, we used the Pediatric Medical Complexity Algorithm (PMCA) (22) to define for each body system an index indicating presence and complexity of chronic condition in that body system grouping and used these PMCA indices in our propensity score model. We then matched PASC patients to comparison patients (SARS-CoV-2 infected patients in the first cohort, SARS-COV-2 uninfected patients in the second cohort) using 5:1 nearest neighbor matching, additionally requiring exact matching on both cohort entry month and age group (23). We assessed the balance between the SARS-CoV-2 infected and uninfected patients via absolute standardized mean differences.

Tree-based scan statistic

The tree-based scan statistic is a data mining tool that is well established in vaccine safety(24) and disease surveillance and characterization(24, 25), making it salient for applications to understand pediatric PASC in its early stages of characterization. This approach simultaneously evaluates outcomes at different levels of granularity in a hierarchical structure, adjusting for multiple testing using a likelihood ratio statistic. In this study, we employed the unconditional analysis based on a Bernoulli probability model at each node of the tree, as described in the TreeScan User's Guide(26). This approach identifies branches of the tree at which outcomes belonged most disproportionately to cases as compared to controls.

As inputs, we used the ICD10CM vocabulary following the ICD10CM Tabular List of Diseases and Injuries(27) as developed by the National Center for Health Statistics (NCHS). For example, a path down the hierarchy might proceed as follows: C00-D49-> C00-C97 -> C44 -> C44.1 -> C44.10 -> C44.102 -> C44.1021. In all, the hierarchy has 7 levels, with the following counts of nodes per level starting from the top down: 22, 262, 2274, 9502, 14400, 22236, 48450.

We will alternately refer to the hierarchy as a tree, and the cluster consisting of a node together with all of its descendants will be referred to as a *branch* of the tree, or equivalently, as a *cut*. For each branch of the tree, we started with the observed count of cases who had an incident diagnosis in that branch during the outcome period. We also calculated the expected number of cases for each branch by multiplying the proportion of cases in the cohort (1/6 due to 5:1 matching) by the number of controls who had an incident diagnosis in the branch. The null hypothesis, for each cut, is that the number of observed cases equals the number of expected

It is made available under a CC-BY-NC-ND 4.0 International license .

cases. This method adjusts for multiple testing in the sense that under the null hypothesis that the number of observed cases equals the number of expected cases at each cut, there is a 95% probability that there is no cut in the tree with a p-value <0.05. For each cut demonstrating significance at the p<0.05 threshold, we calculated percent excess cases as the difference between number of observed cases and the number of expected cases divided by the number of expected cases. Analyses were carried out using R (4.1.0) and Treescan (2.0) software. Subclassification matching was implemented using the MatchIt R package and tree visualizations were built using the collapsibleTree R package.

Outcomes

For each patient and each diagnosis code, we calculated a binary indicator for whether the patient had an incident occurrence of that diagnosis code during the 28-179 days following cohort entry. We then used these to compute for each diagnosis code, and consequently each cluster of diagnosis codes defined by a branch of the tree, the number of cases and controls who had an incident diagnosis in that branch.

To define incident outcomes, we employed a washout period between 18 months and 7 days prior to cohort entry for conditions grouped at the 3rd level of the ICD hierarchy (I.e., the part of the ICD code before the decimal place) to ensure new incident diagnoses. In other words, conditions which occurred during the study period were not counted if a code in the same group occurred during the washout period. We also a priori excluded a handful of outcomes that were deemed unlikely to be attributable to COVID-19, specifically injury codes (S00-T98), external causes of morbidity and mortality (V01-Y98), and congenital malformations, deformations and chromosomal abnormalities (Q00-Q99).

RESULTS

Study population and matching

Between March 1, 2020, and June 22, 2022, there was a total of 13,750 patients identified for inclusion into the 3 cohorts, with PASC cases accounting for 1,250 patients (Table 1a). Older children and females were more likely to be included in the PASC cohort than younger children and males(overall: 55.2% vs 44.8%). The most common cohort entry months were in the fall of 2021. A majority of children in the PASC cohort (55.1%) did not have any chronic conditions. Following 5:1 nearest neighbor matching, both comparison cohorts had excellent balance (|SMD|<0.2 for unknown test location and one site, |SMD|<0.1 for all other variables). (Supplementary Appendix Figures 1a-b). After matching, the demographic distributions of both COVID-positive and COVID-negative cohorts reflect those of the PASC cohort.

TreeScan

When comparing patients with PASC to patients who were SARS-CoV-2 infected, we identified multiple statistical signals. At the highest level of the tree, significant cuts included ROO-R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, MOO-M99 Diseases of the musculoskeletal system and connective tissue, GOO-G99 Diseases of the nervous system, JOO-J99 Diseases of the respiratory system, FOO-F99 Mental and behavioral disorders, EOO-E90 Endocrine, nutritional, and metabolic diseases, IOO-I99 Diseases of the

It is made available under a CC-BY-NC-ND 4.0 International license .

circulatory system, Z00-Z99 Factors influencing health status and contact with health services, L00-L99 Diseases of the skin and subcutaneous tissue, and K00-K93 Diseases of the digestive system.

Within the ROO-R99 branch, the top three cuts were ROO-R09 Symptoms and signs involving the circulatory and respiratory systems, R50-R69 General symptoms and signs and R40-R46 Symptoms and signs involving cognition, perception, emotional state and behavior. Within the ROO-R09 branch, the three most significant cuts included R06.0 Dyspnea, R07 Pain in throat and chest, R09.9 Chest pain, unspecified. This part of the hierarchy is visualized in Figure 3a.

The PASC vs SARS-CoV-2 negative comparison showed significance for 283 cuts, and largely overlapped with the PASC vs SARS-CoV-2 negative comparison at the top of the tree, with the addition of H00-H59 Diseases of the eye and adnexa.

We refer the reader to Table 2 for a summary of systemic and syndromic findings collected from the two comparisons and Tables 3a and 3b for a full list of significant cuts, the likelihood ratio statistics, p-values, and percent excess cases.

DISCUSSION

We have employed a tree-based data mining approach to detect new-onset conditions presenting in children with a PASC (U09.9 or B94.8) diagnosis. Our data-driven approach identified and ranked features in a large corpus of EHR data. In the first of our two primary analyses, we compared PASC-diagnosed patients with non-PASC-diagnosed SARS-CoV-2 positive patients. The signals identified indicate long term sequelae of PASC that differentiate from having COVID-19.

Significant results from this comparison included both systemic and syndromic manifestations of PASC, with the former describing organ-level dysfunction and the latter focusing on signs and symptoms. Consistent with other studies and biologic mechanisms, we found significant enrichment among children with PASC in cardiac, respiratory, neurologic, psychological, endocrine, gastrointestinal, and musculoskeletal systems (28).

We found the most significant point of difference between PASC and COVID-19 positive children was at the R00-R99 cluster of diagnostic codes (*Symptoms, signs, and abnormal clinical and laboratory findings, not otherwise classified*). These codes designate abnormal clinical findings not elsewhere described that encompass a range of organ systems. This is not surprising given the heterogeneity of previously reported manifestations of PASC and the difficulty in gaining clinical consensus to define PASC (29, 30).

Within the ROO-R99 category, the codes with the greatest signal are symptoms related to circulatory and respiratory systems. These results align again with prior observations in smaller groups of patients or previous studies, and include dyspnea(12, 17), shortness of breath(17, 32), and other breathing abnormalities(33); chest pain(10, 34, 35); malaise and fatigue(14, 32,

It is made available under a CC-BY-NC-ND 4.0 International license .

35, 36); cough(14); and abnormalities of heartbeat including palpitations and tachycardia(37, 38).

Neurologic diagnoses such as headache and migraine as well as sleep disturbances are significant cuts and have also been previously reported (12, 33). Generalized pain was a key feature in our musculoskeletal system findings, which include non-localized myalgias, joint pain, and generalized soft tissue pain. The recurring appearance of multiple and diverse pain symptoms in this study warrants further investigation to better characterize causal biologic pathways.

Respiratory conditions were also significantly featured in our analysis. Both vocal cord disorders and dysautonomia were present as PASC-related features in our study. Interestingly, new onset asthma was present in our results as a specific diagnosis rather than a constellation of nonspecific symptoms. Asthma is one of the few specific health conditions with a significant and strong signal in our study. Respiratory findings associated with PASC have been characterized in detail elsewhere (9).

In contrast to previous work, our study did not identify new-onset diabetes as a persistent longterm complication of COVID-19 (40). Endocrine findings in this study included nutritional deficiencies, volume depletion or fluid overload, and obesity. To our knowledge, these symptoms have not been described in detail elsewhere. It is unclear whether clinicians are recording obesity in the post-infection period as an indication that obesity complicated recovery of SARS-CoV-2 infection or that it points to a patient's exacerbation of health conditions unrelated to COVID-19.

Gastrointestinal (e.g., *Diseases of esophagus, stomach and duodenum*) and psychological findings (e.g., *Reaction to severe stress, and adjustment disorders*) followed a pattern of TreeScan cuts primarily at non-specific levels. Future work should focus on characterizing co-occurrences of these non-specific symptoms across body systems to detect clinically meaningful patterns.

We also compared children with a PASC diagnosis code to SARS-CoV-2 test-negative patients. The majority of cuts from this comparator cohort overlap with the findings where SARS-CoV-2 test-positive patients served as the control. These demonstrate consistency and increase the likelihood that these findings are truly associated with PASC. Additionally, several diagnoses unique to the test-negative cohort were identified, many of which include symptoms relating to acute respiratory infection. Some specific infection codes, such as B25, *Cytomegaloviral Disease* (CMV) were found significant, which may be a result of reactivation in patients infected with SARS-CoV-2(41). Other codes, such as D89, *Other disorders involving the immune mechanism, not elsewhere classified*, or skin conditions such as dermatitis and eczema (L20-L30), were also enriched in the PASC patients when compared to SARS-CoV-2 negative patients. Autoimmunity following an infection has been documented and warrants further investigation in the pediatric population(42). Alternate findings enriched in this analysis include features plausibly associated with COVID-19 infection including acute myocarditis, hypotension, fever, nasal congestion,

It is made available under a CC-BY-NC-ND 4.0 International license .

epistaxis, tachycardia, and gastrointestinal symptoms such as diarrhea, constipation, and gastroenteritis. More serious conditions such as pulmonary embolism and pulmonary edema were also enriched in this population but may be due to follow up care from an acute COVID-19 infection, and not a new finding in the post-acute period. However, these findings warrant further investigation. Findings such as sleep apnea, or behavioral codes associated with restlessness and agitation and disorientation, may also be plausibly associated with post-acute sequelae of COVID-19 infection.

Compared to previous work identifying pediatric PASC features by comparing SARS-CoV-2 testpositive to test-negative patients in the PEDSnet EHR, we found several differences. Abnormal liver enzymes, allergies, disorders of teeth/gingiva, and bronchiolitis were all reported as potential PASC-associated features in [18] but were not identified as significant cuts in this study when PASC patients were compared to COVID+ or COVID- cohorts, either at the specific code or macro level. Conversely, significant findings in our study which were not present in [18] included sleep disorders, anemias, eye disorders, constipation, sepsis, nutritional deficiencies, hypotension, and various musculoskeletal conditions and soft tissue and muscle disorders.

Finally, we conducted a sensitivity analysis comparing COVID positive to COVID negative patients. By identifying events that occur in the PASC risk window more frequently in COVID-positive patients, we can increase the sensitivity of capturing potential PASC features. This may come at the expense of precision, as we recognize that statistical signals identified in this analysis may correspond to features not truly associated with PASC, either due to confounding resulting from a more heterogeneous population than PASC-diagnosed patients or due to surveillance bias due to COVID-positivity. While there was significant overlap of the features identified in this and the primary analyses, there were also many additional features identified in the COVID-positive to COVID-negative analysis. This discrepancy may be due to either the increased power resulting from the larger cohort in the sensitivity analysis, or the result of confounding or surveillance bias described above. Further investigation of these signals is warranted.

To our knowledge, our study is the first to employ a TreeScan approach in children to detect groups of clinical diagnoses specific to this population, as well as the first to make use of the U09.9 and B94.8 diagnosis codes to do so. Our study is strengthened by multiple comparison groups diagnoses of PASC rather than surveys or case series analyses. We have confirmed previous findings and provide new insights into how diagnosis clusters relate to each other in importance. Further, an advantage of EHR data is the ability to learn from previous clinical history of patients. In our analysis, we included an 18-month washout period to ensure that the signals we were observing were not due to baseline differences in disease prevalence. Prior work identifying pediatric PASC-associated features [18] relied on a set of diagnosis clusters developed by the study team to group similar diagnoses. Our study addresses this methodological limitation by a broader approach where diagnosis clusters are tested along all levels of the ICD-10-CM hierarchy. Importantly, among features of PASC found in previous work, our study contributes precise, diagnosis code-level results showing how PASC features

It is made available under a CC-BY-NC-ND 4.0 International license .

are identified in clinical practice. This makes our findings ideally suited for development of rules-based phenotypes for identifying pediatric PASC in EHRs.

At the same time, there were several significant limitations to our study. First, we are at risk of misclassifying patients in our PASC-negative comparator cohort by relying solely on the U09.9 and B94.8 codes to identify cases. There are likely children and adolescents in our comparison cohort with complications of COVID-19 who never receive a formal PASC diagnosis and may either present to a health system with symptoms that the clinician did not distinguish as a complication of COVID-19 or may not receive care for their symptoms at all. However, this would likely bias toward the null. Further, the U09.9 code has only been formally implemented since October 2021, and while the B94.8 code likely served as a proxy for PASC prior to this, the likely lack of uniform code usage, particularly early in the pandemic, introduces potential bias with regards to the timing of cohort entry dates in our cohort during the pandemic. Additionally, for PASC-diagnosed and serology test positive patients in our cohort who had no prior COVID diagnoses or positive viral testing, our imputation of cohort entry dates may not accurately reflect timing of COVID infection, and in the case of PASC-diagnosed patients, PASC onset. Second, our ascertainment of other diagnosis codes is similarly subject to the biases of health care delivery. For example, our findings may disproportionately include diagnoses that are required for utilization (e.g., to justify diagnostic testing) or symptoms that are uncommon and previously associated in clinical practice with COVID-19 and may under-detect changes following COVID-19 in relatively common childhood illness that escape coding practices. Third, we have analyzed the pandemic as a single cross-section, and further information may be gained by studying evolution of diagnoses over time since infection, or across different portions of the pandemic. Finally, the cohort is composed of patients followed in large pediatric health systems, and results may reflect the largely urban demographics of these systems or the practice patterns of pediatric specialists.

CONCLUSION

This systematic evaluation of diagnoses in a large, multi-system national cohort of children with PASC provides a valuable addition to our understanding of this condition's protean manifestations. Our results can inform the design of further prospective studies to more deeply investigate the patterns identified here to develop improved clinical practice and to direct the study of the biological basis of PASC.

It is made available under a CC-BY-NC-ND 4.0 International license .

	Level	Overall	SARS CoV-2-	SARS CoV-2-	PASC
		N (%)	negative N (%)	positive N (%)	N (%)
n		13,750	6,250	6,250	1,250
Age at cohort entrance (%)	<1	440 (3.2)	200 (3.2)	200 (3.2)	40 (3.2)
	1-4	1276 (9.3)	580 (9.3)	580 (9.3)	116 (9.3)
	5-11	3542 (25.8)	1610 (25.8)	1610 (25.8)	322 (25.8)
	12-15	4620 (33.6)	2100 (33.6)	2100 (33.6)	420 (33.6)
	16-20	3872 (28.2)	1760 (28.2)	1760 (28.2)	352 (28.2)
Sex (%)	Female	7577 (55.1)	3400 (54.4)	3487 (55.8)	690 (55.2)
	Male	6173 (44.9)	2850 (45.6)	2763 (44.2)	560 (44.8)
Race/ethnicity (%)	Non-Hispanic Asian/PI	422 (3.1)	186 (3.0)	196 (3.1)	40 (3.2)
	Non-Hispanic Black/AA	1255 (9.1)	555 (8.9)	583 (9.3)	117 (9.4)
	Hispanic	2017 (14.7)	905 (14.5)	928 (14.8)	184 (14.7)
	Multiple	566 (4.1)	254 (4.1)	260 (4.2)	52 (4.2)
	Other/Unkno wn	700 (5.1)	316 (5.1)	312 (5.0)	72 (5.8)
	Non-Hispanic White	8790 (63.9)	4034 (64.5)	3971 (63.5)	785 (62.8)
Cohort entry month (%)	Mar 2020	77 (0.6)	35 (0.6)	35 (0.6)	7 (0.6)
	Apr 2020	132 (1.0)	60 (1.0)	60 (1.0)	12 (1.0)
	May 2020	88 (0.6)	40 (0.6)	40 (0.6)	8 (0.6)
	Jun 2020	165 (1.2)	75 (1.2)	75 (1.2)	15 (1.2)
	Jul 2020	154 (1.1)	70 (1.1)	70 (1.1)	14 (1.1)
	Aug 2020	110 (0.8)	50 (0.8)	50 (0.8)	10 (0.8)
	Sep 2020	231 (1.7)	105 (1.7)	105 (1.7)	21 (1.7)
	Oct 2020	242 (1.8)	110 (1.8)	110 (1.8)	22 (1.8)
	Nov 2020	385 (2.8)	175 (2.8)	175 (2.8)	35 (2.8)
	Dec 2020	396 (2.9)	180 (2.9)	180 (2.9)	36 (2.9)
	Jan 2021	506 (3.7)	230 (3.7)	230 (3.7)	46 (3.7)
	Feb 2021	264 (1.9)	120 (1.9)	120 (1.9)	24 (1.9)
	Mar 2021	451 (3.3)	205 (3.3)	205 (3.3)	41 (3.3)
	Apr 2021	473 (3.4)	215 (3.4)	215 (3.4)	43 (3.4)
	May 2021	341 (2.5)	155 (2.5)	155 (2.5)	31 (2.5)
	Jun 2021	495 (3.6)	225 (3.6)	225 (3.6)	45 (3.6)
	Jul 2021	517 (3.8)	235 (3.8)	235 (3.8)	47 (3.8)
	Aug 2021	792 (5.8)	360 (5.8)	360 (5.8)	72 (5.8)

Table 1. Study population characteristics after matching

It is made available under a CC-BY-NC-ND 4.0 International license .

670 (10.7)

540 (8.6)

510 (8.2)

890 (14.2)

995 (15.9)

518 (8.3)

692 (11.1)

1191 (19.1)

177 (2.8)

437 (7.0)

262 (4.2)

594 (9.5)

1041 (16.7)

1338 (21.4)

969 (15.5)

782 (12.5)

2792 (44.7)

1670 (26.7)

3370 (53.9)

1948 (31.2)

932 (14.9)

37 (0.6)

670 (10.7)

540 (8.6)

510 (8.2)

890 (14.2)

995 (15.9)

437 (7.0)

715 (11.4)

1125 (18.0)

183 (2.9)

513 (8.2)

224 (3.6)

600 (9.6)

1121 (17.9)

1332 (21.3)

1032 (16.5)

891 (14.3)

2671 (42.7)

1646 (26.3)

3377 (54.0)

2013 (32.2)

860 (13.8)

10 (0.2)

134 (10.7)

108 (8.6)

102 (8.2)

178 (14.2)

199 (15.9)

158 (12.6)

237 (19.0)

37 (3.0)

98 (7.8)

60 (4.8)

113 (9.0)

223 (17.8)

240 (19.2)

178 (14.2)

162 (13.0)

556 (44.5)

321 (25.7)

689 (55.1)

378 (30.2)

183 (14.6)

33 (2.6)

84 (6.7)

medRxiv preprint doi: https://doi.org/10.1101/2022.12.08.22283158; this version posted December 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

1474 (10.7)

1188 (8.6)

1122 (8.2)

1958 (14.2)

2189 (15.9)

1039 (7.6)

1565 (11.4)

2553 (18.6)

397 (2.9)

1048 (7.6)

546 (4.0)

1307 (9.5)

2385 (17.3)

2910 (21.2)

2179 (15.8)

1835 (13.3)

6019 (43.8)

3637 (26.5)

7436 (54.1)

4339 (31.6)

1975 (14.4)

80 (0.6)

Sep 2021

Oct 2021

Nov 2021

Dec 2021

Jan 2022

Α

В

С

D

Е

F

G

Η

Ι

wn

0

1

2

Office Outpatient:

Emergency

Department Inpatient

Other/Unkno

Outpatient

Test Only

Institution (%)

Test Location

PMCA Index

(%)

(%)

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2: Summary of significant features in the two comparison cohorts							
Major systemic findings, or conditions (general and specific)							
Diseases of the nervous	migraines, headache syndromes, sleep disorders, insomnia, chronic pain, dysautonomia, post-viral fatigue syndrome,						
system	encephalitis, disorders of autonomic nervous system, sleep						
	apnea*, transverse myelitis*						
Mental and behavioral	anxiety disorders, severe stress and adjustment disorders, organic						
disorders	including symptomatic mental disorders, obsessive-compulsive						
	disorder, dissociative and conversion disorders*						
Diseases of the	asthma, ARDS/respiratory failure, diseases of vocal cords and						
respiratory system	larynx, tonsilitis, exercise induced bronchospasm*, chronic						
	sinusitis*, pulmonary edema*,						
Diseases of the	arrhythmias, cerebrovascular disease, thromboembolic disease,						
circulatory system	acute myocarditis*, hypotension*, pulmonary embolism*,						
	tachycardia*,						
Disease of the	pain in joints, pain in limbs, dorsalgia, myalgias, hypermobility						
musculoskeletal system	syndrome, soft tissue disorders, muscle disorders, arthropathies,						
and connective tissue	osteopathies, disorders of bone, reactive arthritis, physeal arrest						
Diseases of the digestive	Diseases of oesophagus, stomach, and duodenum, aphagia and						
system	dysphagia						
Diseases of blood	purpura and other hemorrhagic conditions*, anemias*, sickle cell						
	disorders*						
Endocrine, nutritional	nutritional deficiencies, obesity and overweight, disorders of						
and metabolic diseases	mineral metabolism, volume depletion or fluid overload, obesity						
Renal	Acute kidney failure*						
Diseases of the eye	Disorders of refraction and accommodation*						
Immunologic findings	Other disorders involving the immune mechanism not elsewhere						
	classified, cytomegaloviral disease*						
Circulatory and	Major syndromic findings, or symptoms						
Circulatory and respiratory signs and	Palpitations, cough, dyspnea, shortness of breath, chest pain, viral pneumonia, asphyxia and hypoxemia*, hyperglycemia*						
symptoms	pheamonia, aspriykia and hypokenna , hypergrycenna						
GI signs/symptoms	abdominal pain, nausea/vomiting, diarrhea*, constipation*,						
	gastroenteritis*						
CNS/musculoskeletal	lack of coordination, abnormalities of gait and mobility						
signs/symptoms							
Cognition, perception,	dizziness, smell/taste disturbances, restlessness and agitation*,						

Table 2: Summary of significant features in the two comparison cohorts

It is made available under a CC-BY-NC-ND 4.0 International license .

emotional state	disorientation*, shock*
General signs and symptoms	Fatigue/malaise, headache, weakness, syncope and collapse, pain not elsewhere classified, fever*, enlarged lymph node, nasal congestion*, epistaxis*, noninflammatory disorders of female genital tract*
Skin	Symptoms and signs involving the skin and subcutaneous tissue, dermatitis,* eczema,* urticaria* and erythema*

*Findings significant in PASC vs COVID-negative comparison but not PASC vs COVID-positive comparison

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3a: Significant branches of the ROO-RO9 block of the ICD hierarchy with nodes colored by percent excess cases





Figure 3b: Significant branches of the R10-R19 block of the ICD hierarchy with nodes colored by percent excess cases



It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3a: PASC vs COVID positive comparison TreeScan results

Cut	Node A00-B99	Tree Level	Log Likelihood Ratio infections and	P value	N cases observed	N cases expected	Percent excess cases
6	B90-B94 Sequelae of infectious and parasitic diseases	2	327.89	0.001	183	30.50	500.00
7	B94 Sequelae of other and unspecified infectious and parasitic diseases	3	327.89	0.001	183	30.50	500.00
8	B94.8 Sequelae of other specified infectious and parasitic diseases	4	326.10	0.001	182	30.33	500.07
14	A00-B99 Certain infections and parasitic diseases	1	157.15	0.001	1,006	167.67	141.55
139	B95-B98 Bacterial, viral and other infectious agents	2	11.37	0.002	259	43.17	71.42
148	B97 Viral agents as the cause of diseases classified elsewhere	3	10.81	0.005	120	20.00	105.00
149	A65-A69 Other spirochaetal diseases	2	10.68	0.009	16	2.67	311.99
158	B25-B34 Other viral diseases	2	10.00	0.014	214	35.67	73.82
D50	-D89 Diseases of the blood		od-forming o mune mecha		nd certain di	sorders invo	lving the
33	D89.89 Other specified disorders involving the immune mechanism, not elsewhere classified	5	55.21	0.001	44	7.33	432.06
49	D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	1	39.94	0.001	901	150.17	71.81
56	D89 Other disorders involving the immune	3	35.01	0.001	93	15.50	229.03

	mechanism, not						
	elsewhere classified						
58	D89.8 Other specified disorders involving the immune mechanism, not elsewhere classified	4	32.12	0.001	83	13.83	232.61
72	D80-D89 Certain disorders involving the immune mechanism	2	23.01	0.001	287	47.83	98.62
	E00-E90 End	locrine,	nutritional ar	nd meta	bolic disease	es	
30	E00-E90 Endocrine, nutritional and metabolic diseases	1	60.96	0.001	1,480	246.67	69.05
51	E70-E88 Metabolic disorders	2	39.53	0.001	631	105.17	86.36
112	E87 Other disorders of fluid, electrolyte and acid-base balance	3	15.36	0.001	194	32.33	97.96
113	E65-E68 Obesity and other hyperalimentation	2	15.28	0.001	182	30.33	101.12
119	E66 Overweight and obesity	3	14.12	0.001	179	29.83	97.79
131	E83 Disorders of mineral metabolism	3	12.30	0.001	142	23.67	102.79
141	E86 Volume depletion	3	11.31	0.002	106	17.67	115.05
145	E86.0 Dehydration	4	11.10	0.005	99	16.50	118.18
151	E50-E64 Other nutritional deficiencies	2	10.67	0.009	137	22.83	97.11
	F00-F9	99 Ment	al and behav	ioural di	sorders		
28	F00-F99 Mental and behavioural disorders	1	68.24	0.001	1,776	296.00	66.55
52	F40-F48 Neurotic, stress- related and somatoform disorders	2	39.33	0.001	543	90.50	93.37
88	F41.9 Anxiety disorder, unspecified	4	19.15	0.001	194	32.33	110.33
89	F41 Other anxiety disorders	3	19.05	0.001	264	44.00	93.18
90	F80-F89 Disorders of psychological development	2	18.82	0.001	422	70.33	72.05
144	F00-F09 Organic, including symptomatic,	2	11.11	0.004	35	5.83	208.75

	mental disorders						
		G99 Die	eases of the r	ervous	system		
15	G00-G99 Diseases of the	1	155.02	0.001	2,238	373.00	91.15
	nervous system						
29	G89-G99 Other disorders of the nervous system	2	66.03	0.001	519	86.50	126.59
32	G40-G47 Episodic and paroxysmal disorders	2	59.22	0.001	1,365	227.50	70.99
46	G89.29 Other chronic pain	5	40.51	0.001	201	33.50	162.69
48	G89.2 Chronic pain, not elsewhere classified	4	40.12	0.001	202	33.67	161.36
50	G89 Pain, not elsewhere classified	3	39.59	0.001	268	44.67	137.30
54	G00-G09 Inflammatory diseases of the central nervous system	2	36.23	0.001	61	10.17	293.31
57	G43 Migraine	3	32.23	0.001	301	50.17	115.27
64	G04 Encephalitis, myelitis and encephalomyelitis	3	25.52	0.001	40	6.67	304.80
68	G47 Sleep disorders	3	24.39	0.001	481	80.17	77.12
69	G43.0 Migraine without aura	4	23.67	0.001	116	19.33	163.84
71	G44 Other headache syndromes	3	23.21	0.001	87	14.50	189.66
74	G44.5 Complicated headache syndromes	4	22.55	0.001	22	3.67	390.46
77	G90.9 Disorder of the autonomic nervous system, unspecified	4	20.93	0.001	19	3.17	404.73
79	G90 Disorders of autonomic nervous system	3	20.55	0.001	38	6.33	279.15
82	G04.8 Other encephalitis, myelitis and encephalomyelitis	4	19.85	0.001	24	4.00	350.00
86	G44.52 New daily persistent headache (NDPH)	5	19.31	0.001	18	3.00	400.00
94	G93.3 Postviral fatigue syndrome	4	18.16	0.001	13	2.17	453.00
111	G43.009 Migraine	6	15.37	0.001	55	9.17	194.44

 without aura, not intractable, without status migrainosus 114 G93 Other disorders of brain G43.00 Migraine without aura, not intractable 15.25 0.001 174 29.00 103.45 14.26 0.001 64 10.67 171.75 133 G04.81 Other encephalitis and encephalomyelitis 166 G47.9 Sleep disorder, 4 9.47 0.023 74 12.33 127.05 	
status migrainosusichichichichich114G93 Other disorders of brain315.250.00117429.00103.43118G43.00 Migraine without aura, not intractable514.260.0016410.67171.73133G04.81 Other encephalitis and encephalitis and encephalitis512.110.001172.83324.03	
114 G93 Other disorders of brain 3 15.25 0.001 174 29.00 103.44 118 G43.00 Migraine without aura, not intractable 5 14.26 0.001 64 10.67 171.74 133 G04.81 Other encephalitis and encephalitis 5 12.11 0.001 17 2.83 324.04	
brainbrainichichichichichichich118G43.00 Migraine without aura, not intractable514.260.0016410.67171.79133G04.81 Other encephalitis and encephalitis and 	
118G43.00 Migraine without aura, not intractable514.260.0016410.67171.79133G04.81 Other encephalitis and encephalomyelitis512.110.001172.83324.09	.79
aura, not intractableImage: second secon	.79
133G04.81 Other encephalitis and encephalomyelitis512.110.001172.83324.03	
encephalitis and encephalomyelitis	
encephalomyelitis	.03
166 G47.9 Sleep disorder, 4 9.47 0.023 74 12.33 127.09	
	.09
unspecified	
167 G43.01 Migraine without 5 9.46 0.023 52 8.67 153.75	.75
aura, intractable	
100-199 Diseases of the circulatory system	
35 100-199 Diseases of the 1 53.46 0.001 948 158.00 81.65 circulatory system)5
41 I30-I52 Other forms of 2 45.42 0.001 335 55.83 131.00	06
heart disease	.00
87 149 Other cardiac 3 19.26 0.001 51 8.50 229.4	11
arrhythmias	.41
122 149.8 Other specified 4 13.45 0.001 34 5.67 235.10	10
cardiac arrhythmias	.10
132 I51 Complications and ill- 3 12.12 0.001 59 9.83 164.50	50
defined descriptions of	
heart disease	
J00-J99 Diseases of the respiratory system	
18 J00-J99 Diseases of the 1 99.31 0.001 2,514 419.00 67.54	54
respiratory system	
45 J40-J47 Chronic lower 2 42.07 0.001 669 111.50 86.55	55
respiratory diseases	
47 J45 Asthma 3 40.37 0.001 648 108.00 86.11	1
70 J30-J39 Other diseases of 2 23.64 0.001 459 76.50 77.78	78
upper respiratory tract	
75 J45.9 Other and 4 21.90 0.001 203 33.83 115.73	.78
unspecified asthma	
80 J96-J99 Other diseases of 2 20.15 0.001 374 62.33 79.69	59
the respiratory system	
109 J35 Chronic diseases of 3 15.52 0.001 78 13.00 161.54	.54
tonsils and adenoids	
115 J45.909 Unspecified 6 14.48 0.001 153 25.50 107.84	.84
asthma, uncomplicated	
121 J45.90 Unspecified 5 13.60 0.001 169 28.17 98.79	'9

_							
	asthma						
123	J96.0 Acute respiratory failure	4	13.36	0.001	95	15.83	133.73
125	J12.8 Other viral pneumonia	4	12.87	0.001	32	5.33	237.71
129	J45.4 Moderate persistent asthma	4	12.36	0.001	106	17.67	120.71
143	J03 Acute tonsillitis	3	11.17	0.004	26	4.33	246.42
147	J45.40 Moderate persistent asthma, uncomplicated	5	11.00	0.005	84	14.00	128.57
150	J80-J84 Other respiratory diseases principally affecting the interstitium	2	10.67	0.009	39	6.50	192.31
152	J96.01 Acute respiratory failure with hypoxia	5	10.63	0.009	49	8.17	169.28
153	J98 Other respiratory disorders	3	10.57	0.010	150	25.00	92.00
154	J20-J22 Other acute lower respiratory infections	2	10.47	0.011	46	7.67	173.79
157	J96 Respiratory failure, not elsewhere classified	3	10.30	0.012	221	36.83	73.77
159	J45.99 Other asthma	5	9.99	0.014	34	5.67	199.82
165	J12 Viral pneumonia, not elsewhere classified	3	9.48	0.023	45	7.50	166.67
	K00-ł	(93 Dise	ases of the d	igestive	system		
135	KOO-K93 Diseases of the digestive system	1	11.86	0.001	1,776	296.00	26.69
137	K2O-K31 Diseases of oesophagus, stomach and duodenum	2	11.40	0.002	318	53.00	64.15
			f the skin and				
127	LOO-L99 Diseases of the skin and subcutaneous tissue	1	12.67	0.001		135.83	41.35
	M00-M99 Diseases o	f the m	usculoskeleta	-	n and conne	ctive tissue	
13	M00-M99 Diseases of the musculoskeletal system and connective tissue	1	170.35	0.001	2,580	430.00	88.84
25	M20-M25 Other joint	2	68.87	0.001	837	139.50	100.00

	disorders						
31	M25 Other joint disorder, not elsewhere classified	3	59.85	0.001	545	90.83	116.89
34	M79 Other and unspecified soft tissue disorders, not elsewhere classified	3	53.49	0.001	365	60.83	136.73
37	M70-M79 Other soft tissue disorders	2	50.12	0.001	391	65.17	127.10
39	M25.5 Pain in joint	4	46.27	0.001	393	65.50	121.37
43	M79.1 Myalgia	4	42.95	0.001	87	14.50	265.52
66	M25.50 Pain in unspecified joint	5	25.07	0.001	38	6.33	310.74
67	M79.10 Myalgia, unspecified site	5	24.76	0.001	46	7.67	278.10
81	M02.30 Reiter's disease, unspecified site	5	19.87	0.001	14	2.33	457.94
84	M30-M36 Systemic connective tissue disorders	2	19.49	0.001	82	13.67	177.98
85	M02.3 Reiter's disease	4	19.42	0.001	16	2.67	424.34
92	M79.18 Myalgia, other site	5	18.28	0.001	41	6.83	251.39
93	M35 Other systemic involvement of connective tissue	3	18.18	0.001	33	5.50	281.82
96	M35.7 Hypermobility syndrome	4	18.05	0.001	21	3.50	357.14
98	M02 Postinfective and reactive arthropathies	3	17.71	0.001	17	2.83	394.70
101	M00-M02 Infectious arthropathies	2	17.25	0.001	24	4.00	325.00
103	M79.6 Pain in limb, hand, foot, fingers and toes	4	16.64	0.001	238	39.67	91.58
104	M60-M63 Disorders of muscles	2	16.55	0.001	316	52.67	78.47
106	M86-M90 Other osteopathies	2	15.80	0.001	117	19.50	130.77
107	M62 Other disorders of muscle	3	15.74	0.001	312	52.00	76.92
128	M62.8 Other specified	4	12.60	0.001	278	46.33	72.67

_							
	disorders of muscle	_			_		
138	M89.1 Physeal arrest	4	11.38	0.002	9	1.50	433.33
140	M89 Other disorders of bone	3	11.37	0.002	44	7.33	186.49
146	M79.60 Pain in limb, unspecified	5	11.10	0.005	99	16.50	118.18
156	M50-M54 Other dorsopathies	2	10.37	0.012	243	40.50	70.37
170	M25.57 Pain in ankle and joints of foot	5	9.10	0.024	53	8.83	149.15
172	M54 Dorsalgia	3	9.00	0.025	225	37.50	68.00
R	00-R99 Symptoms, signs ar	nd abno	rmal clinical a	nd labo	ratory findir	ngs, not else	where
			classified				
1	R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	1	696.14	0.001	7,440	1,240.00	107.18
9	R00-R09 Symptoms and signs involving the circulatory and respiratory systems	2	315.26	0.001	1,768	294.67	152.15
10	R06.0 Dyspnea	4	205.81	0.001	282	47.00	327.66
11	R50-R69 General symptoms and signs	2	187.76	0.001	1,975	329.17	108.10
12	R06 Abnormalities of breathing	3	172.25	0.001	564	94.00	204.26
16	R53 Malaise and fatigue	3	130.02	0.001	380	63.33	217.39
17	R53.8 Other malaise and fatigue	4	116.09	0.001	311	51.83	228.00
19	R06.00 Dyspnea, unspecified	5	91.08	0.001	100	16.67	367.91
20	R06.02 Shortness of breath	5	85.46	0.001	116	19.33	329.38
21	R53.83 Other fatigue	5	80.62	0.001	207	34.50	233.33
22	R40-R46 Symptoms and signs involving cognition, perception, emotional state and behaviour	2	77.91	0.001	665	110.83	121.06
23	R10-R19 Symptoms and signs involving the digestive system and abdomen	2	71.22	0.001	1,508	251.33	74.27

24	R07 Pain in throat and	3	69.87	0.001	280	46.67	182.84
	chest						182.84
36	R42 Dizziness and giddiness	3	51.34	0.001	137	22.83	228.52
38	R07.9 Chest pain, unspecified	4	46.88	0.001	154	25.67	203.86
40	R06.09 Other forms of dyspnea	5	45.94	0.001	34	5.67	446.74
42	R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems	2	44.32	0.001	272	45.33	144.87
44	R00 Abnormalities of heart beat	3	42.38	0.001	217	36.17	159.88
53	R51 Headache	3	36.56	0.001	208	34.67	150.94
55	R51.9 Headache, unspecified	4	35.57	0.001	193	32.17	154.90
59	R10 Abdominal and pelvic pain	3	31.59	0.001	523	87.17	84.70
60	R00.2 Palpitations	4	30.93	0.001	82	13.67	229.19
61	R05 Cough	3	29.56	0.001	348	58.00	101.72
62	R53.82 Chronic fatigue, unspecified	5	27.98	0.001	33	5.50	354.55
63	R07.89 Other chest pain	5	25.79	0.001	85	14.17	203.46
65	R07.8 Other chest pain	4	25.20	0.001	99	16.50	184.85
73	R29 Other symptoms and signs involving the nervous and musculoskeletal systems	3	22.64	0.001	151	25.17	138.38
76	R05.3 Chronic cough	4	21.81	0.001	34	5.67	305.64
78	R68 Other general symptoms and signs	3	20.62	0.001	110	18.33	156.41
83	R43 Disturbances of smell and taste	3	19.53	0.001	34	5.67	288.01
91	R70-R79 Abnormal findings on examination of blood, without diagnosis	2	18.64	0.001	300	50.00	86.00
95	R11 Nausea and vomiting	3	18.05	0.001	427	71.17	70.02
97	R90-R96 Abnormal findings on diagnostic imaging and in function	2	17.75	0.001	279	46.50	87.10

	studies, without diagnosis						
99	R68.89 Other general symptoms and signs	5	17.64	0.001	83	13.83	167.53
100	R55 Syncope and collapse	3	17.32	0.001	77	12.83	172.80
102	R68.8 Other general symptoms and signs	4	16.84	0.001	92	15.33	154.40
105	R43.9 Unspecified disturbances of smell and taste	4	16.12	0.001	16	2.67	386.89
108	R41 Other symptoms and signs involving cognitive functions and awareness	3	15.58	0.001	133	22.17	121.02
110	R53.1 Weakness	4	15.42	0.001	68	11.33	173.61
116	R00.0 Tachycardia, unspecified	4	14.44	0.001	99	16.50	136.36
124	R10.84 Generalized abdominal pain	5	13.03	0.001	147	24.50	104.08
126	R53.81 Other malaise	5	12.87	0.001	71	11.83	153.59
130	R27 Other lack of coordination	3	12.34	0.001	42	7.00	200.00
134	R10.8 Other abdominal pain	4	11.97	0.001	160	26.67	94.98
136	R09 Other symptoms and signs involving the circulatory and respiratory system	3	11.60	0.001	271	45.17	70.47
155	R05.9 Cough, unspecified	4	10.38	0.012	194	32.33	79.40
160	R11.10 Vomiting, unspecified	5	9.94	0.015	201	33.50	76.12
161	R46.81 Obsessive- compulsive behavior	5	9.71	0.020	8	1.33	426.32
162	R29.90 Unspecified symptoms and signs involving the nervous system	5	9.69	0.023	10	1.67	379.04
163	R13 Aphagia and dysphagia	3	9.54	0.023	267	44.50	64.04
164	R13.1 Dysphagia	4	9.54	0.023	267	44.50	64.04
168	R59.1 Generalized	4	9.28	0.023	15	2.50	300.00

It is made available under a CC-BY-NC-ND 4.0 International license .

169 171	enlarged lymph nodes R06.8 Other abnormalities of breathing R41.8 Other symptoms and signs involving cognitive functions and	4	9.15 9.09	0.024	224 99	37.33 16.50	68.77 106.06
	awareness		adas for spar	مسيما من			
2	U09 Post COVID-19	3	Codes for spec 492.73	0.001	275	45.83	500.04
2	condition	5	492.75	0.001	275	43.65	500.04
3	U09.9 Post COVID-19 condition, unspecified	4	492.73	0.001	275	45.83	500.04
4	U00-U95 Codes for special purposes	1	408.47	0.001	630	105.00	307.62
5	U00-U49 Provisional assignment of new diseases of uncertain etiology or emergency use	2	408.47	0.001	630	105.00	307.62
26	U07.1 Emergency use of U07.1 COVID-19	4	68.29	0.001	355	59.17	158.58
27	U07	3	68.29	0.001	355	59.17	158.58
	Z00-Z99 Factors influe	encing h	ealth status a	nd cont	act with hea	lth services	
117	Z00-Z99 Factors influencing health status and contact with health services	1	14.42	0.001	1,774	295.67	29.54
120	Z69-Z76 Persons encountering health services in other circumstances	2	13.64	0.001	254	42.33	79.54

Table 2b: PASC vs COVID negative comparison TreeScan results

Cut	Node	Tree	Log	Р	N cases	N cases	Percent
		Level	Likelihood	value	observed	expected	excess

			Ratio				cases
	A00-B99	Certain i	nfections and	l parasit	ic diseases		
7	B90-B94 Sequelae of infectious and parasitic diseases	2	327.89	0.001	183	30.50	500.00
8	B94 Sequelae of other and unspecified infectious and parasitic diseases	3	327.89	0.001	183	30.50	500.00
9	B94.8 Sequelae of other specified infectious and parasitic diseases	4	326.10	0.001	182	30.33	500.07
14	A00-B99 Certain infections and parasitic diseases	1	245.33	0.001	796	132.67	205.27
75	B95-B98 Bacterial, viral and other infectious agents	2	31.80	0.001	175	29.17	153.69
94	B97 Viral agents as the cause of diseases classified elsewhere	3	26.25	0.001	78	13.00	215.38
117	B25-B34 Other viral diseases	2	22.14	0.001	160	26.67	132.47
177	A30-A49 Other bacterial diseases	2	14.78	0.001	53	8.83	194.45
203	A65-A69 Other spirochaetal diseases	2	12.98	0.001	14	2.33	372.10
207	B97.89 Other viral agents as the cause of diseases classified elsewhere	5	12.54	0.002	48	8.00	187.50
216	B34 Viral infection of unspecified site	3	12.28	0.002	122	20.33	111.51
220	B97.8 Other viral agents as the cause of diseases classified elsewhere	4	12.08	0.002	49	8.17	181.52
232	B25 Cytomegaloviral disease	3	11.38	0.002	9	1.50	433.33
D50	-D89 Diseases of the blood		od-forming or mune mechar	-	id certain di	sorders invo	lving the
23	D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the	1	124.54	0.001	575	95.83	169.23

	immune mechanism						
40	D89.89 Other specified disorders involving the immune mechanism, not elsewhere classified	5	59.62	0.001	42	7.00	457.14
51	D80-D89 Certain disorders involving the immune mechanism	2	51.91	0.001	198	33.00	187.88
66	D89 Other disorders involving the immune mechanism, not elsewhere classified	3	41.12	0.001	84	14.00	264.29
67	D89.8 Other specified disorders involving the immune mechanism, not elsewhere classified	4	40.07	0.001	72	12.00	283.33
102	D60-D64 Aplastic and other anaemias	2	24.97	0.001	130	21.67	158.42
146	D65-D69 Coagulation defects, purpura and other haemorrhagic conditions	2	17.60	0.001	73	12.17	179.38
157	D55-D59 Haemolytic anaemias	2	16.08	0.001	33	5.50	263.64
161	D64 Other anemias	3	15.91	0.001	77	12.83	165.00
166	D70-D77 Other diseases of blood and blood- forming organs	2	15.70	0.001	81	13.50	159.26
184	D57 Sickle-cell disorders	3	14.39	0.001	22	3.67	308.72
202	D69 Purpura and other hemorrhagic conditions	3	13.02	0.001	47	7.83	193.74
214	D64.9 Anemia, unspecified	4	12.30	0.002	62	10.33	161.37
249	D57.4 Sickle-cell thalassemia	4	10.75	0.005	6	1.00	500.00
255	D84 Other immunodeficiencies	3	10.35	0.005	94	15.67	116.98
	E00-E90 End	ocrine,	nutritional ar	nd meta	bolic disease	es	
25	E00-E90 Endocrine, nutritional and metabolic diseases	1	113.64	0.001	1,205	200.83	107.64
37	E70-E88 Metabolic disorders	2	72.43	0.001	498	83.00	136.14

62	E87 Other disorders of fluid, electrolyte and acid-base balance	3	43.15	0.001	118	19.67	225.37
105	E86 Volume depletion	3	24.49	0.001	72	12.00	216.67
114	E86.0 Dehydration	4	22.76	0.001	69	11.50	213.04
139	E65-E68 Obesity and other hyperalimentation	2	18.20	0.001	170	28.33	115.32
148	E66 Overweight and obesity	3	17.20	0.001	166	27.67	113.23
181	E83 Disorders of mineral metabolism	3	14.53	0.001	133	22.17	116.51
222	E50-E64 Other nutritional deficiencies	2	11.80	0.002	132	22.00	104.55
223	E66.9 Obesity, unspecified	4	11.75	0.002	67	11.17	150.67
244	E87.7 Fluid overload	4	11.08	0.002	32	5.33	218.95
254	E87.70 Fluid overload, unspecified	5	10.49	0.005	30	5.00	220.00
	F00-F9	9 Ment	al and behavi	oural di	sorders		
26	F00-F99 Mental and	1	107.08	0.001	1,548	258.00	91.09
	behavioural disorders						
48	F40-F48 Neurotic, stress- related and somatoform disorders	2	53.47	0.001	483	80.50	117.39
87	F41 Other anxiety disorders	3	27.79	0.001	228	38.00	123.68
88	F41.9 Anxiety disorder, unspecified	4	27.37	0.001	166	27.67	145.75
91	F80-F89 Disorders of psychological development	2	26.88	0.001	377	62.83	92.58
182	F44 Dissociative and conversion disorders	3	14.49	0.001	13	2.17	406.91
217	F00-F09 Organic, including symptomatic, mental disorders	2	12.25	0.002	33	5.50	227.27
221	F90-F98 Behavioural and emotional disorders with onset usually occurring in childhood and adolescence	2	11.80	0.002	165	27.50	92.73
256	F88 Other disorders of psychological	3	10.28	0.005	143	23.83	93.03

development Image: style s	3.67	
		254.22
G00-G99 Diseases of the nervous system		
16 G00-G99 Diseases of the 1 226.27 0.001 1,937	322.83	120.86
nervous system		
31 G40-G47 Episodic and 2 93.82 0.001 1,177 paroxysmal disorders 2 93.82 0.001 1,177	196.17	98.30
33 G89-G99 Other disorders 2 81.51 0.001 471	78.50	149.68
of the nervous system		
44 G43 Migraine 3 58.59 0.001 226	37.67	186.70
54G89 Pain, not elsewhere349.640.001240classified	40.00	165.00
55G00-G09 Inflammatory248.470.00150diseases of the central nervous system	8.33	380.19
58 G89.29 Other chronic 5 45.09 0.001 190 pain	31.67	177.87
59G89.2 Chronic pain, not444.650.001191elsewhere classified	31.83	176.47
71 G44 Other headache 3 33.99 0.001 69 syndromes	11.50	265.22
72G04 Encephalitis, myelitis333.820.00133and encephalomyelitis	5.50	390.91
80 G47 Sleep disorders 3 30.02 0.001 450	75.00	89.33
81 G43.0 Migraine without 4 29.98 0.001 102 aura	17.00	200.00
93 G90 Disorders of 3 26.47 0.001 32 autonomic nervous system	5.33	350.28
107G44.5 Complicated424.190.00121headache syndromes	3.50	414.29
116G04.8 Other encephalitis, myelitis and encephalomyelitis422.550.00122	3.67	390.46
120 G93.3 Postviral fatigue 4 21.50 0.001 12 syndrome	2.00	500.00
132G44.52 New daily persistent headache (NDPH)519.310.00118	3.00	400.00
138 G93 Other disorders of brain 3 18.25 0.001 162	27.00	118.52
142 G90.9 Disorder of the 4 18.05 0.001 21	3.50	357.14

autonomic nervous system, unspecified is is is in the intervolus system, unspecified is is is is in the intervolus aura, intractable is is is is is in the intervolus intractable, without status migrainosus is i	_							
162 G43.01 Migraine without aura, intractable 5 15.81 0.001 39 6.50 238.46 176 G43.009 Migraine without aura, not intractable, without status migrainosus 6 14.88 0.001 56 9.33 189.39 178 G43.00 Migraine without aura, not intractable 5 14.69 0.001 63 10.50 176.19 180 G04.81 Other eccephalomyelitis 5 14.54 0.001 15 2.50 380.00 204 G44.8 Other specified headache syndromes 4 12.98 0.001 14 2.33 372.10 180 G60.G65 2 11.33 0.002 253 42.17 75.48 235 G60.G65 2 11.33 0.002 23 3.83 265.54 Polyneuropathies and other disorders of the peripheral nervous system 5 11.27 0.002 11 1.83 391.80 241 G43.019 Migraine without status migrainosus 6 11.09 0.002 29 4.83 231.26 241 G43.019 Migraine without status smigrainosus 6 10.95 0.		autonomic nervous						
aura, intractableor		• •						
without aura, not intractable, without status migrainosus 5 14.69 0.001 63 10.50 176.19 178 G43.00 Migraine without aura, not intractable 5 14.69 0.001 15 2.50 380.00 180 G04.81 Other encephalitis and encephalomyelitis 5 14.54 0.001 15 2.50 380.00 204 G44.80 Other specified headache syndromes 4 12.32 0.002 253 42.17 75.48 235 G60-G65 2 11.33 0.002 23 3.83 265.54 Polyneuropathies and other disorders of the peripheral nervous system 5 11.27 0.002 11 1.83 391.80 237 G44.89 Other headache syndrome 5 11.27 0.002 11 1.83 391.80 241 ed3.019 Migraine without aura, intractable, without status migrainosus 4 10.75 0.002 29 4.83 231.26 250 G43.9 Migraine, unspecified 4 9.16 0.01 39 6.50 176.92 26 G43.9 Migraine, unspecified 4 9.16 0.01<	162	-	5	15.81	0.001	39	6.50	238.46
aura, not intractableout	176	without aura, not intractable, without	6	14.88	0.001	56	9.33	189.39
encephalitis and encephalomyelitisimage: image: im	178	-	5	14.69	0.001	63	10.50	176.19
headache syndromesImage: Constraint of the syndromesImage: Constraint of the syndromeImage: Constraint of the syndromeImage: Constraint of the syndrome237G60-G65 Polyneuropathies and other disorders of the peripheral nervous system211.330.002233.83265.54237G44.89 Other headache syndrome511.270.002111.83391.80241G43.019 Migraine without aura, intractable, without status migrainosus611.090.002294.83231.26250G37.3 Acute transverse myelitis in demyelinating disease of central nervous system410.750.00561.00500.00280G43.9 Migraine, unspecified49.160.014396.50176.92120.560.001790131.6754.17120.560.001790131.6754.17120.560.001790131.6754.17120.560.001790131.6754.17120.560.001790131.6754.17120.560.001790131.6754.17120.560.001790131.6754.17120.560.001790131.6754.1710.0810.00234156.8360.131	180	encephalitis and	5	14.54	0.001	15	2.50	380.00
235 G60-G65 2 11.33 0.002 23 3.83 265.54 Polyneuropathies and other disorders of the peripheral nervous system 11.27 0.002 11 1.83 391.80 237 G44.89 Other headache syndrome 5 11.27 0.002 11 1.83 391.80 241 G43.019 Migraine without aura, intractable, without status migrainosus 6 11.09 0.002 29 4.83 231.26 250 G37.3 Acute transverse myelitis in demyelinating disease of central nervous system 4 10.75 0.005 6 1.00 500.00 280 G43.9 Migraine, unspecified 4 9.16 0.014 39 6.50 176.92 284 H49-H52 Disorders of eye and adnexa 1 20.56 0.001 790 131.67 54.17 284 H49-H52 Disorders of ocular muscles, binocular movement, accommodation and refraction 1 0.014 0.002 341 56.83 60.13 294 H52 Disorders of 3 10.14 0.005 231 38.5	204	-	4	12.98	0.001	14	2.33	372.10
Polyneuropathies and other disorders of the peripheral nervous systemImage: systemImage: systemImage: systemImage: system237644.89 Other headache syndrome511.270.002111.83391.80241643.019 Migraine without aura, intractable, without status migrainosus611.090.002294.83231.26250637.3 Acute transverse myelitis in demyelinating disease of central nervous system410.750.00561.00500.00280643.9 Migraine, unspecified49.160.014396.50176.92H00-H59 Diseases of the eye and adnexa120.560.001790131.6754.17281H49-H52 Disorders of ocular muscles, binocular movement, accommodation and refraction310.140.00523138.5071.43	212	G47.3 Sleep apnea	4	12.32	0.002	253	42.17	75.48
syndromeincomeincomeincomeincome241G43.019 Migraine without aura, intractable, without status migrainosus611.090.002294.83231.26250G37.3 Acute transverse myelitis in demyelinating disease of central nervous system410.750.00561.00500.00280G43.9 Migraine, unspecified49.160.014396.50176.92Introving systemIntroving system	235	Polyneuropathies and other disorders of the peripheral nervous	2	11.33	0.002	23	3.83	265.54
without aura, intractable, without status migrainosusis	237		5	11.27	0.002	11	1.83	391.80
myelitis in demyelinating disease of central nervous systemis subsetis subsetis subset280G43.9 Migraine, unspecified49.160.014396.50176.92HO0-H59 Diseases of the eye and adnexa120.560.001790131.6754.17248H49-H52 Disorders of ocular muscles, binocular movement, accommodation and refraction210.810.00234156.8360.13260H52 Disorders of310.140.00523138.5071.43	241	without aura, intractable, without status	6	11.09	0.002	29	4.83	231.26
unspecifiedImage: Second s	250	myelitis in demyelinating disease of central	4	10.75	0.005	6	1.00	500.00
126 H00-H59 Diseases of the eye and adnexa 1 20.56 0.001 790 131.67 54.17 248 H49-H52 Disorders of ocular muscles, binocular movement, accommodation and refraction 2 10.81 0.002 341 56.83 60.13 260 H52 Disorders of 3 10.14 0.005 231 38.50 71.43	280	- .	4	9.16	0.014	39	6.50	176.92
eye and adnexaindextindextindextindext248H49-H52 Disorders of ocular muscles, binocular movement, accommodation and refraction210.81 indext0.002341 indext56.83 indext60.13 indext260H52 Disorders of M 52 Disorders of310.140.00523138.5071.43		H00-I	159 Dise	ases of the e	ye and a	adnexa		
ocular muscles, binocular movement, accommodation and refractionsetsetsetsetsetsetset260H52 Disorders of310.140.00523138.5071.43	126		1	20.56	0.001	790	131.67	54.17
	248	ocular muscles, binocular movement, accommodation and refraction	2	10.81	0.002	341	56.83	60.13
	260		3	10.14	0.005	231	38.50	71.43

	accommodation						
			ses of the circ	ulator	auctom		
29	100-199 Diseases of the	9 Diseas		0.001	740	1 7 7 7 7 7	122 71
29	circulatory system		102.68	0.001	740	123.33	132.71
39	l30-l52 Other forms of heart disease	2	60.44	0.001	292	48.67	165.05
110	l49 Other cardiac arrhythmias	3	23.44	0.001	45	7.50	273.33
141	l49.8 Other specified cardiac arrhythmias	4	18.10	0.001	28	4.67	306.85
154	195-199 Other and unspecified disorders of the circulatory system	2	16.34	0.001	50	8.33	212.12
172	I51 Complications and ill- defined descriptions of heart disease	3	15.28	0.001	52	8.67	199.88
173	l95 Hypotension	3	15.24	0.001	37	6.17	240.36
211	I26-I28 Pulmonary heart disease and diseases of pulmonary circulation	2	12.43	0.002	45	7.50	193.33
257	I40 Acute myocarditis	3	10.27	0.005	14	2.33	329.18
258	I26 Pulmonary embolism	3	10.27	0.005	14	2.33	329.18
	100-19	9 Diseas	es of the res	piratory	system		
15	J00-J99 Diseases of the respiratory system	1	234.13	0.001	1,867	311.17	125.60
35	J40-J47 Chronic lower respiratory diseases	2	75.13	0.001	534	89.00	133.71
36	J45 Asthma	3	73.86	0.001	512	85.33	135.56
63	J30-J39 Other diseases of upper respiratory tract	2	43.01	0.001	370	61.67	120.53
68	J45.9 Other and unspecified asthma	4	39.96	0.001	152	25.33	188.20
70	J96-J99 Other diseases of the respiratory system	2	34.25	0.001	309	51.50	117.48
79	J45.909 Unspecified asthma, uncomplicated	6	30.15	0.001	108	18.00	194.44
85	J12.8 Other viral pneumonia	4	28.52	0.001	19	3.17	467.82
89	J96.0 Acute respiratory failure	4	26.97	0.001	65	10.83	241.64
92	J45.90 Unspecified asthma	5	26.54	0.001	126	21.00	166.67
	ustinnu						

100 100-106 Acute upper respiratory infections 2 24.94 0.001 391 65.17 87.20 104 109-118 Influenza and pneumonia 2 24.74 0.001 110 18.33 172.78 111 135 Chronic diseases of tonsils and adenoids 3 23.34 0.001 62 10.33 229.14 121 112.82 Pneumonia due to coronavirus disease 2019 5 21.50 0.001 12 2.00 500.00 134 J80-J84 Other respiratory diseases principally affecting the interstitium disorders 3 19.04 0.001 118 19.67 144.03 136 J96.01 Acute respiratory failure with hypoxia 3 18.70 0.001 35 5.83 277.36 135 J96.Acute respiratory failure with hypoxia 3 16.54 0.001 92 15.33 154.40 153 J96.Acute respiratory failure, not elsewhere classified 3 16.25 0.001 190 31.67 102.08 170 J45.90 Other asthma 5 15.33 0.001		elsewhere classified						
respiratory infections respiratory infections respiratory infections respiratory infections 104 J09-J18 influenza and pueumonia 2 24.74 0.001 110 18.33 172.78 111 J35 Chronic diseases of consils and adenoids 3 23.34 0.001 62 10.33 229.14 121 J2.82 Pneumonia due to coronavirus disease 2016 5 2.150 0.001 12 2.00 500.00 127 J80-J84 Other respiratory diseases principally affecting the interstitium 2 20.17 0.001 18 9.67 144.03 136 J96.01 Acute respiratory failure with hypoxia 3 18.70 0.001 18 9.67 144.03 151 J03 Acute tonsillitis 3 16.54 0.001 20 3.33 350.45 1515 J96 Respiratory failure, and factor 5 15.30 0.001 20 3.33 292.61 152 J45.40 Moderate persistent asthma 5 15.30 0.001 20 3.33 292.61 <td< th=""><th>103</th><th></th><th>2</th><th>24.94</th><th>0.001</th><th>391</th><th>65.17</th><th>87.20</th></td<>	103		2	24.94	0.001	391	65.17	87.20
104 J09-J18 influenza and pneumonia 2 24.74 0.001 110 18.33 172.78 111 J35 Chronic diseases of and adenoids 3 23.34 0.01 62 10.33 229.14 121 J35 Chronic diseases 2019 5 21.50 0.01 12 2.00 500.00 122 J80-J84 Other respiratory disease principally affecting the interstitum 5 21.50 0.01 12 2.00 500.00 134 J88 Other respiratory disorders 3 19.04 0.01 188 19.67 144.03 136 J86 Other respiratory failure with hypoxia 5 18.70 0.01 35 5.83 277.36 153 J03 Acute respiratory failure, not elsewhere classified not elsewhere elsewhere el		• •	-	2.110.1	0.001		0011/	07120
tonsils and adenoidsimage of the second	104	J09-J18 Influenza and	2	24.74	0.001	110	18.33	172.78
coronavirus disease 2019 coronavirus disease 2019 127 180-184 Other respiratory diseases principally affecting the interstitium affecting the interstitient affecting the intersters affend affecting the interstitient affecting the interstiti	111		3	23.34	0.001	62	10.33	229.14
diseases principally affecting the interstitiumincincincincincincinc134J98 Other respiratory disorders319.040.00111819.67144.03136J96.01 Acute respiratory failure with hypoxia518.700.001355.83277.36152J45.4 Moderate persistent asthma416.840.0019215.33154.40153J03 Acute tonsillitis316.540.001203.33350.45155J96 Respiratory failure, not elsewhere classified316.250.00119031.67102.08170J45.90 Other asthma515.330.001264.33292.61188J45.40 Moderate persistent asthma, uncomplicated514.000.0017512.50156.00200J80 Acute respiratory distress syndrome313.060.001101.67438.92218J45.90 Exercise induced bronchospasm612.540.002193.17310.09230J45.30 Mild persistent asthma uncomplicated511.410.0029415.6712.336244J32-Uronic sinusitis311.090.002294.83231.26245J32 Chronic sinusitis311.090.002294.83231.26246J32-Uronic sinusitis311.090.002294.83231.26247J20	121		5	21.50	0.001	12	2.00	500.00
disorders disorders disorders disorders disorders 136 J96.01 Acute respiratory failure with hypoxia 5 18.70 0.001 35 5.83 277.36 152 J45.4 Moderate persistent asthma 4 16.84 0.001 92 15.33 154.40 153 J03 Acute tonsillitis 3 16.54 0.001 20 3.33 350.45 155 J96 Respiratory failure, not elsewhere classified 3 16.25 0.001 190 31.67 102.08 170 J45.90 Other asthma 5 15.33 0.001 26 4.33 292.61 188 J45.40 Moderate persistent asthma, uncomplicated 5 14.00 0.001 75 12.50 156.00 200 J80 Acute respiratory distress syndrome 3 13.06 0.001 10 1.67 438.92 213 J45.30 Mild persistent asthma, uncomplicated 6 12.54 0.002 19 3.17 310.09 230 J45.30 Mild persistent asthma		diseases principally affecting the interstitium		20.17		26	4.33	338.80
failure with hypoxia indext of the second seco	134	· ·	3	19.04	0.001	118	19.67	144.03
image: persistent asthmaimage: persistent asthmaimage: persistent asthmaimage: persistent asthmaimage: persistent asthmaimage: persistent asthmaimage: persistent asthma, uncomplicatedimage: p	136	failure with hypoxia	5	18.70	0.001		5.83	277.36
155 J96 Respiratory failure, not elsewhere classified 3 16.25 0.001 190 31.67 102.08 170 J45.99 Other asthma 5 15.33 0.001 26 4.33 292.61 188 J45.40 Moderate persistent asthma, uncomplicated 5 14.00 0.001 75 12.50 156.00 200 J80 Acute respiratory distress syndrome 3 13.06 0.001 10 1.67 438.92 208 J45.990 Exercise induced distress syndrome 6 12.54 0.002 19 3.17 310.09 208 J45.30 Mild persistent asthma, uncomplicated 5 11.41 0.002 19 3.17 310.09 230 J45.30 Mild persistent asthma 5 11.41 0.002 94 15.67 123.36 234 J45.3 Mild persistent asthma 9 11.30 0.002 110 18.33 112.77 235 J45.3 Mild persistent asthma 9 10.91 0.002 29 4.83 231.26 244 J32 Chronic sinusitis 3 11.09 0.002 29	152		4	16.84	0.001	92	15.33	154.40
not elsewhere classified in the elsewhere classified i	153	J03 Acute tonsillitis	3	16.54	0.001	20	3.33	350.45
188 J45.40 Moderate persistent asthma, uncomplicated 5 14.00 0.001 75 12.50 156.00 200 J80 Acute respiratory distress syndrome 3 13.06 0.001 10 1.67 438.92 208 J45.990 Exercise induced bronchospasm 6 12.54 0.002 19 3.17 310.09 230 J45.30 Mild persistent asthma, uncomplicated 5 11.41 0.002 94 15.67 123.36 242 J32 Chronic sinusitis 3 11.09 0.002 10 18.33 112.77 244 J32 Chronic sinusitis 3 11.09 0.002 29 4.83 231.26 247 J20-J22 Other acute lower respiratory infections 3 11.09 0.002 45 7.50 180.00 25 J03.9 Acute tonsillitis, unspecified 4 9.92 0.008 12 2.00 350.00 269 J35.3 Hypertrophy of tonsils with hypertrophy 4 9.77 0.008 17 2.83 288.69	155	· · ·	3	16.25	0.001	190	31.67	102.08
persistent asthma, uncomplicatedinsert is in the second s	170	J45.99 Other asthma	5	15.33	0.001	26	4.33	292.61
distress syndrome Image: Marcine and M	188	persistent asthma,	5	14.00	0.001	75	12.50	156.00
bronchospasm Image: second secon	200	• •	3	13.06	0.001	10	1.67	438.92
asthma, uncomplicated Image: Marking and Mar	208		6	12.54	0.002	19	3.17	310.09
asthmaindexindexindexindexindexindexindex242J32 Chronic sinusitis311.090.002294.83231.26247J20-J22 Other acute lower respiratory infections210.910.002457.50180.00265J03.9 Acute tonsillitis, unspecified49.920.008122.00350.00269J35.3 Hypertrophy of tonsils with hypertrophy49.770.008172.83288.69	230	•	5	11.41	0.002	94	15.67	123.36
247 J20-J22 Other acute lower respiratory infections 2 10.91 0.002 45 7.50 180.00 265 J03.9 Acute tonsillitis, unspecified 4 9.92 0.008 12 2.00 350.00 269 J35.3 Hypertrophy of tonsils with hypertrophy 4 9.77 0.008 17 2.83 288.69	236	•	4	11.30	0.002	110	18.33	112.77
lower respiratory infectionslewlewlewlewlew265J03.9 Acute tonsillitis, unspecified49.920.008122.00350.00269J35.3 Hypertrophy of tonsils with hypertrophy49.770.008172.83288.69	242	J32 Chronic sinusitis	3	11.09	0.002	29	4.83	231.26
unspecifiedImage: specifiedImage: specifiedImage: specifiedImage: specified269J35.3 Hypertrophy of tonsils with hypertrophy49.770.008172.83288.69	247	lower respiratory infections	2	10.91	0.002	45	7.50	
tonsils with hypertrophy	265	· ·	4	9.92	0.008	12	2.00	350.00
		tonsils with hypertrophy of adenoids						
270 J81 Pulmonary edema 3 9.71 0.010 8 1.33 426.32	270	J81 Pulmonary edema	3	9.71	0.010	8	1.33	426.32

271	J35.0 Chronic tonsillitis	4	9.69	0.013	10	1.67	379.04
	and adenoiditis						
272	J35.01 Chronic tonsillitis	5	9.69	0.013	10	1.67	379.04
			ases of the di	-	-		
53	K00-K93 Diseases of the digestive system	1	49.78	0.001	1,366	227.67	64.71
125	K55-K64 Other diseases of intestines	2	20.89	0.001	485	80.83	70.73
147	K59 Other functional intestinal disorders	3	17.52	0.001	390	65.00	72.31
150	K59.0 Constipation	4	17.06	0.001	375	62.50	72.80
169	K2O-K31 Diseases of oesophagus, stomach and duodenum	2	15.57	0.001	291	48.50	79.38
171	K59.00 Constipation, unspecified	5	15.28	0.001	211	35.17	93.35
198	K52 Other and unspecified noninfective gastroenteritis and colitis	3	13.24	0.001	70	11.67	157.07
213	K31.8 Other specified diseases of stomach and duodenum	4	12.30	0.002	30	5.00	240.00
263	KOO-K14 Diseases of oral cavity, salivary glands and jaws	2	10.04	0.007	140	23.33	92.88
264	K52.9 Noninfective gastroenteritis and colitis, unspecified	4	10.03	0.007	54	9.00	155.56
	L00-L99 Dise	eases of	the skin and	subcuta	neous tissu	е	
82	LOO-L99 Diseases of the skin and subcutaneous tissue	1	29.50	0.001	672	112.00	71.43
179	L49-L54 Urticaria and erythema	2	14.59	0.001	44	7.33	213.78
189	L20-L30 Dermatitis and eczema	2	13.89	0.001	201	33.50	91.04
261	L30 Other and unspecified dermatitis	3	10.06	0.005	47	7.83	168.20
279	L30.9 Dermatitis, unspecified	4	9.16	0.014	39	6.50	176.92
	M00-M99 Diseases o	f the mu	ısculoskeletal	system	and connec	tive tissue	
18	M00-M99 Diseases of the musculoskeletal system	1	172.11	0.001	2,571	428.50	89.50

	and connective tissue						
38	M79 Other and	3	61.70	0.001	341	56.83	153.39
50	unspecified soft tissue	5	01.70	0.001	341	50.05	133.33
	disorders, not elsewhere						
	classified						
41	M70-M79 Other soft	2	58.99	0.001	363	60.50	144.63
	tissue disorders						
49	M25 Other joint disorder,	3	53.27	0.001	571	95.17	107.00
	not elsewhere classified						
50	M20-M25 Other joint	2	52.61	0.001	918	153.00	82.35
50	disorders	4	F1 F2	0.001	275	() [0	122.00
52 61	M25.5 Pain in joint M79.1 Myalgia	4	51.53 43.72	0.001 0.001	375 86	62.50 14.33	132.00 269.85
83	M79.10 Myalgia,	5	29.36	0.001	41	6.83	324.60
00	unspecified site	5	23.30	0.001	4	0.05	524.00
90	M86-M90 Other	2	26.97	0.001	89	14.83	203.44
	osteopathies						
100	M02.3 Reiter's disease	4	25.08	0.001	14	2.33	500.86
101	M02 Postinfective and	3	25.08	0.001	14	2.33	500.86
106	reactive arthropathies M00-M02 Infectious	2	24.43	0.001	19	3.17	436.28
100	arthropathies	Z	24.45	0.001	19	5.17	430.28
112	M02.30 Reiter's disease,	5	23.29	0.001	13	2.17	499.08
	unspecified site						
123	M79.6 Pain in limb, hand, foot, fingers and toes	4	21.35	0.001	217	36.17	110.12
128	M50-M54 Other	2	20.15	0.001	194	32.33	113.42
	dorsopathies	-	20120	0.001	201	0 2100	110111
130	M54 Dorsalgia	3	19.76	0.001	172	28.67	119.74
133	M89 Other disorders of	3	19.04	0.001	32	5.33	294.00
	bone						
140	M25.50 Pain in	5	18.10	0.001	47	7.83	232.06
151	unspecified joint	2	17.02	0.001	0.0	14 67	150.02
151	M30-M36 Systemic connective tissue	2	17.03	0.001	88	14.67	159.03
	disorders						
156	M60-M63 Disorders of	2	16.21	0.001	318	53.00	77.36
	muscles						
165	M79.18 Myalgia, other	5	15.74	0.001	45	7.50	220.00
	site						
168	M62 Other disorders of	3	15.57	0.001	313	52.17	76.35
100	muscle	F	14 45	0.001	00	14.67	145 40
183	M79.60 Pain in limb,	5	14.45	0.001	88	14.67	145.40

	unspecified						
185	M25.56 Pain in knee	5	14.35	0.001	103	17.17	132.96
194	M35 Other systemic involvement of connective tissue	3	13.42	0.001	40	6.67	214.84
199	M35.7 Hypermobility syndrome	4	13.17	0.001	26	4.33	269.52
201	M24.9 Joint derangement, unspecified	4	13.06	0.001	10	1.67	438.92
210	M62.8 Other specified disorders of muscle	4	12.44	0.002	279	46.50	72.04
233	M89.1 Physeal arrest	4	11.38	0.002	9	1.50	433.33
282	M25.561 Pain in right knee	6	9.08	0.017	46	7.67	160.76
	N00-N99) Diseas	es of the geni	itourina	ry system		
137	N17 Acute kidney failure	3	18.45	0.001	38	6.33	263.35
158	N00-N99 Diseases of the genitourinary system	1	15.99	0.001	615	102.50	54.15
192	N17.9 Acute kidney failure, unspecified	4	13.45	0.001	34	5.67	235.10
227	N17-N19 Renal failure	2	11.55	0.002	64	10.67	153.05
259	N80-N98 Noninflammatory disorders of female genital tract	2	10.25	0.005	186	31.00	80.65
R	00-R99 Symptoms, signs an	d abnor	mal clinical a classified	nd labo	ratory findin	igs, not else	where
1	R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	1	1,145.85	0.001	5,963	993.83	158.49
4	R00-R09 Symptoms and signs involving the circulatory and respiratory systems	2	508.76	0.001	1,357	226.17	228.51
10	R50-R69 General symptoms and signs	2	299.48	0.001	1,606	267.67	155.91
13	R06.0 Dyspnea	4	245.38	0.001	250	41.67	382.36
17	R06 Abnormalities of breathing	3	214.14	0.001	494	82.33	247.38
19	R53 Malaise and fatigue	3	164.37	0.001	328	54.67	267.66
20	R53.8 Other malaise and	4	149.00	0.001	265	44.17	284.88

Index Index<		fatigue						
chest	21	R40-R46 Symptoms and signs involving cognition, perception, emotional	2	135.61	0.001	507	84.50	189.94
signs involving the digestive system and abdomen signs involving the digestive system and giddiness signs involving the digestive system and giddiness signs involving the digestive system signs involving the digestive system digestive system digestive system digestive system digestive system 40 R05 Cough 3 S3.96 0.001 263 S1.80 25.17 25.714 47 R05 Cough 3 S3.96 0.001 263 S1.80 25.17	22		3	131.20	0.001	189	31.50	319.05
unspecifiedone <td>24</td> <td>signs involving the digestive system and</td> <td>2</td> <td>122.47</td> <td>0.001</td> <td>1,253</td> <td>208.83</td> <td>109.74</td>	24	signs involving the digestive system and	2	122.47	0.001	1,253	208.83	109.74
breath inclusion inclusion inclusion inclusion 30 R53.83 Other fatigue 5 96.11 0.001 185 30.83 273.01 32 R00 Abnormalities of heart beat 3 85.44 0.001 143 23.83 294.46 34 R07.9 Chest pain, unspecified 4 81.42 0.001 108 18.00 333.33 42 R51 Headache 3 58.90 0.001 160 26.67 226.21 43 R42 Dizziness and giddiness 3 58.64 0.001 126 21.00 257.14 45 R00.2 Palpitations 4 57.94 0.001 54 9.00 400.00 46 R51.9 Headache, unspecified 4 57.40 0.001 151 25.17 225.78 47 R05 Cough 3 53.96 0.001 263 5.50 463.64 dyspnea 5 84.36 0.001 33 5.50 453.64 5	27		5	106.60	0.001	90	15.00	420.00
32 R00 Abnormalities of heart beat 3 85.44 0.001 143 23.83 294.46 34 R07.9 Chest pain, unspecified 4 81.42 0.001 108 18.00 333.33 42 R51 Headache 3 58.90 0.001 160 26.67 226.21 43 R42 Dizziness and giddiness 3 58.64 0.001 126 21.00 257.14 45 R00.2 Palpitations 4 57.94 0.001 54 9.00 400.00 46 R51.9 Headache, unspecified 4 57.94 0.001 151 25.17 225.78 47 R05 Cough 3 53.96 0.001 33 5.50 463.64 dyspnea 2 47.51 0.001 33 5.50 463.64 dyspnea 2 47.51 0.001 33 5.50 463.64 dyspnea 2 47.51 0.001 33 5.50 43.64 dyspnea	28		5	104.66	0.001	101	16.83	393.17
heart beaticiticiticiticiticiticit34R07.9 Chest pain, unspecified481.420.00110818.0033.3342R51 Headache358.900.00116026.67226.2143R42 Dizziness and giddiness358.640.00112621.00257.1445R00.2 Palpitations457.940.001549.00400.0046R51.9 Headache, unspecified355.400.00115125.17225.7847R05 Cough353.960.00126744.50162.9256R06.09 Other forms of dyspnea548.360.001335.50463.6457R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems444.080.0017011.67302.7460R07.8 Other chest pain542.300.00126311.67302.7461R11 Nausea and vomiting pelvic pain341.470.00131853.00128.3062R10 Abdominal and pelvic pain338.640.00148881.3397.9673R43 Disturbances of smell and taste332.900.001244.00450.0074R50 Fever of other and unknown origin322.910.00116627.67160.21	30	R53.83 Other fatigue	5	96.11	0.001	185	30.83	273.01
inspecifiedinspecifiedinspecifiedinspecifiedinspecified42R51 Headache358.900.00116026.67226.2143R42 Dizziness and giddiness358.640.00112621.00257.1445R00.2 Palpitations457.940.001549.00400.0046R51.9 Headache, unspecified455.400.00115125.17225.7847R05 Cough353.960.00126744.50162.9256R06.09 Other forms of dyspnea548.360.001335.50463.6477R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems247.510.00126343.83153.2560R07.8 Other chest pain542.300.0016210.33316.2661R11 Nausea and vomiting341.470.00131853.00128.3069R10 Abdominal and pelvic pain332.900.00148881.3397.9673R43 Disturbances of smell and taste322.940.00116627.67160.2174R50 Fever of other and unknown origin332.540.00116627.67160.21	32		3	85.44	0.001	143	23.83	294.46
43R42 Dizziness and giddiness358.640.00112621.00257.1445R00.2 Palpitations457.940.001549.00400.0046R51.9 Headache, unspecified455.400.00115125.17225.7847R05 Cough353.960.00126744.50162.9256R06.09 Other forms of dyspnea548.360.001335.50463.6457R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems444.080.0017011.67302.7460R07.8 Other chest pain542.300.0016210.33316.2665R11 Nausea and vomiting341.470.00131853.00128.3069R10 Abdominal and pelvic pain332.900.001244.00450.0074R35 Fever of other and unknown origin332.540.00116627.67160.21	34	• •	4	81.42	0.001	108	18.00	333.33
ieidinessieidinessieidinessieidinessieidinessieidiness45R00.2 Palpitations457.940.001549.00400.0046R51.9 Headache, unspecified455.400.00115125.17225.7847R05 Cough353.960.00126744.50162.9256R06.09 Other forms of dyspnea548.360.001335.50463.6457R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems444.080.0017011.67302.7460R07.8 Other chest pain444.080.0017011.67302.7464R07.89 Other chest pain542.300.0016210.33316.2665R11 Nausea and vomiting341.470.00131853.00128.3069R43 Disturbances of smell and taste332.900.001244.00450.0074R50 Fever of other and unknown origin332.540.00116627.67160.21	42	R51 Headache	3	58.90	0.001	160	26.67	226.21
46R51.9 Headache, unspecified455.400.00115125.17225.7847R05 Cough353.960.00126744.50162.9256R06.09 Other forms of dyspnea548.360.001335.50463.6457R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems247.510.00126343.83153.2560R07.8 Other chest pain444.080.0017011.67302.7464R07.89 Other chest pain542.300.00131853.00128.3065R11 Nausea and vomiting pelvic pain338.640.00148881.3397.9673R43 Disturbances of smell and taste332.540.00116627.67160.2174R50 Fever of other and unknown origin332.540.00116627.67160.21	43		3	58.64	0.001	126	21.00	257.14
Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal system10Normal system1000000000000000000000000000000000000	45	R00.2 Palpitations	4	57.94	0.001	54	9.00	400.00
56 R06.09 Other forms of dyspnea 5 48.36 0.001 33 5.50 463.64 57 R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems 2 47.51 0.001 263 43.83 153.25 60 R07.8 Other chest pain 4 44.08 0.001 70 11.67 302.74 64 R07.89 Other chest pain 5 42.30 0.001 62 10.33 316.26 65 R11 Nausea and vomiting 3 38.64 0.001 488 81.33 97.96 69 R43 Disturbances of smell and taste 3 32.90 0.001 24 4.00 450.00 74 R50 Fever of other and unknown origin 3 32.54 0.001 166 27.67 160.21	46	· ·	4	55.40	0.001	151	25.17	225.78
dyspneadyspneaiceiceiceiceiceiceiceice57R25-R29 Symptoms and signs involving the nervous and musculoskeletal systems247.510.00126343.83153.2560R07.8 Other chest pain444.080.0017011.67302.7464R07.89 Other chest pain542.300.0016210.33316.2665R11 Nausea and vomiting341.470.00131853.00128.3069R10 Abdominal and pelvic pain338.640.00148881.3397.9673R43 Disturbances of smell and taste332.900.001244.00450.0074R50 Fever of other and unknown origin332.540.00116627.67160.21	47	R05 Cough	3	53.96	0.001	267	44.50	162.92
signs involving the nervous and musculoskeletal systemsimage: signs involving the nervous and signs involving the signs involving the signs involving the signs involving the signs involving the nervous and musculoskeletal systemsimage: signs involving the nervous and the signs involving the signs invol	56		5	48.36	0.001	33	5.50	463.64
64 R07.89 Other chest pain 5 42.30 0.001 62 10.33 316.26 65 R11 Nausea and vomiting 3 41.47 0.001 318 53.00 128.30 69 R10 Abdominal and pelvic pain 3 38.64 0.001 488 81.33 97.96 73 R43 Disturbances of smell and taste 3 32.90 0.001 24 4.00 450.00 74 R50 Fever of other and unknown origin 3 32.54 0.001 166 27.67 160.21		signs involving the nervous and musculoskeletal systems	2	47.51			43.83	
65 R11 Nausea and vomiting 3 41.47 0.001 318 53.00 128.30 69 R10 Abdominal and pelvic pain 3 38.64 0.001 488 81.33 97.96 73 R43 Disturbances of smell and taste 3 32.90 0.001 24 4.00 450.00 74 R50 Fever of other and unknown origin 3 32.54 0.001 166 27.67 160.21	60	· · ·	4					
69 R10 Abdominal and pelvic pain 3 38.64 0.001 488 81.33 97.96 73 R43 Disturbances of smell and taste 3 32.90 0.001 24 4.00 450.00 74 R50 Fever of other and unknown origin 3 32.54 0.001 166 27.67 160.21		•						
pelvic painImage: spelvic painImage: spelvic painImage: spelvic painImage: spelvic pain73R43 Disturbances of smell and taste332.900.001244.00450.0074R50 Fever of other and unknown origin332.540.00116627.67160.21								
smell and tasteImage: smell and tasteImage: smell and tasteImage: smell and taste74S50 Fever of other and unknown origin332.540.00116627.67160.21		pelvic pain						
unknown origin	73		3	32.90	0.001	24	4.00	450.00
76 R70-R79 Abnormal 2 31.70 0.001 245 40.83 127.77	74		3	32.54	0.001	166	27.67	160.21
	76	R70-R79 Abnormal	2	31.70	0.001	245	40.83	127.77

	findings on examination of blood, without diagnosis						
77	R09 Other symptoms and signs involving the circulatory and respiratory system	3	30.64	0.001	189	31.50	144.44
78	R00.0 Tachycardia, unspecified	4	30.15	0.001	66	11.00	254.55
84	R90-R96 Abnormal findings on diagnostic imaging and in function studies, without diagnosis	2	28.55	0.001	233	38.83	124.05
86	R53.81 Other malaise	5	27.84	0.001	45	7.50	300.00
95	R05.3 Chronic cough	4	26.19	0.001	30	5.00	360.00
97	R53.82 Chronic fatigue, unspecified	5	25.68	0.001	35	5.83	328.82
99	R41 Other symptoms and signs involving cognitive functions and awareness	3	25.46	0.001	105	17.50	180.00
108	R68 Other general symptoms and signs	3	23.85	0.001	102	17.00	176.47
109	R50.9 Fever, unspecified	4	23.46	0.001	127	21.17	155.08
113	R19 Other symptoms and signs involving the digestive system and abdomen	3	23.28	0.001	117	19.50	161.54
118	R05.9 Cough, unspecified	4	21.87	0.001	146	24.33	138.39
119	R11.10 Vomiting, unspecified	5	21.77	0.001	150	25.00	136.00
122	R29 Other symptoms and signs involving the nervous and musculoskeletal systems	3	21.37	0.001	155	25.83	132.29
124	R2O-R23 Symptoms and signs involving the skin and subcutaneous tissue	2	20.91	0.001	195	32.50	115.38
129	R43.9 Unspecified disturbances of smell and taste	4	19.87	0.001	14	2.33	457.94
131	R55 Syncope and collapse	3	19.58	0.001	72	12.00	191.67

135	R68.8 Other general	4	18.79	0.001	87	14.50	168.97
	symptoms and signs	_					
143	R68.89 Other general	5	18.05	0.001	82	13.67	170.67
111	symptoms and signs	4	17.00	0.001	170	20.02	111 20
144	R11.1 Vomiting	4	17.92	0.001	179	29.83	111.20
145	R53.1 Weakness	4	17.72	0.001	63	10.50	195.24
149	R06.8 Other abnormalities of	4	17.18	0.001	182	30.33	107.72
	breathing						
159	R09.02 Hypoxemia	5	15.96	0.001	57	9.50	194.74
160	R09.0 Asphyxia and	4	15.96	0.001	57	9.50	194.74
100	hypoxemia	-	13.50	0.001	57	5.50	134.74
163	R10.8 Other abdominal	4	15.76	0.001	144	24.00	116.67
	pain		2017 0	0.001		2	110.07
164	R19.7 Diarrhea,	4	15.74	0.001	74	12.33	167.64
	unspecified						
167	R11.0 Nausea	4	15.58	0.001	71	11.83	170.50
174	R09.8 Other specified	4	15.11	0.001	127	21.17	122.01
	symptoms and signs						
	involving the circulatory						
	and respiratory systems						
175	R10.84 Generalized	5	15.01	0.001	139	23.17	115.80
	abdominal pain	_			_		
187	R29.90 Unspecified	5	14.33	0.001	8	1.33	501.50
	symptoms and signs						
	involving the nervous system						
190	R41.8 Other symptoms	4	13.69	0.001	83	13.83	145.84
190	and signs involving	4	13.09	0.001	00	13.03	143.04
	cognitive functions and						
	awareness						
191	R63	3	13.68	0.001	232	38.67	83.60
193	R27 Other lack of	3	13.42	0.001	40	6.67	214.84
	coordination						
195	R45 Symptoms and signs	3	13.36	0.001	114	19.00	121.05
	involving emotional state						
196	R13.1 Dysphagia	4	13.27	0.001	243	40.50	80.25
197	R13 Aphagia and	3	13.27	0.001	243	40.50	80.25
	dysphagia						
205	R29.9 Unspecified	4	12.88	0.001	12	2.00	400.00
	symptoms and signs						
	involving the nervous						
	and musculoskeletal						

systems Image: Systems Systems Image: Systems <thimage: systems<="" th=""> Image: Systems</thimage:>	206							
findings of blood chemistryincincincincinc215R04 Hemorrhage from respiratory passages312.280.002396.50207.69218R59 Enlarged lymph nodes312.250.002366.00216.67224R70311.740.002152.50340.00225R91.8 Other nonspecific abnormal finding of lung field311.730.002284.67242.61226R93 Abnormal findings on diagnostic imaging of other body structures311.640.002508.33176.11228R46 Symptoms and signs behavior311.530.0028614.33130.29231R09.81 Nasal congestion electrocardiogram [ECG] [EKG]511.410.0029415.67123.36238R41.0 Disorientation, unspecified411.270.002111.83391.80238R41.9 Disorientation, unspecified411.270.002111.83391.80239R47-R49 Symptoms and signs involving speech and voice311.260.0027212.00141.67234R91 Abnormal findings on diagnostic imaging of on diagnostic imaging of on diagnostic imaging of311.080.0027212.00141.67	200		4	12.88	0.001	12	2.00	400.00
respiratory passages Image: Construct of the second s	209	findings of blood	3	12.52	0.002	137	22.83	105.87
IndesIndexIndexIndexIndex224R70311.740.002152.50340.00225R91.8 Other nonspecific abnormal finding of lung field411.730.002284.67242.61226R93 Abnormal findings on diagnostic imaging of other body structures311.640.002508.33176.11228R46 Symptoms and signs involving appearance and behavior311.530.0028614.33130.29231R09.81 Nasal congestion electrocardiogram [ECG] [EKG]511.410.0029415.67123.36238R41.0 Disorientation, unspecified411.270.002111.83391.80239R47-R49 Symptoms and signs involving speech and voice211.260.0027212.00141.67243R91 Abnormal findings on diagnostic imaging of on diagnostic imaging of311.080.002325.33218.95	215	-	3	12.28	0.002	39	6.50	207.69
225R91.8 Other nonspecific abnormal finding of lung field411.730.002284.67242.61226R93 Abnormal findings on diagnostic imaging of other body structures311.640.002508.33176.11228R46 Symptoms and signs involving appearance and behavior311.530.0028614.33130.29231R09.81 Nasal congestion511.410.0029415.67123.36234R94.31 Abnormal electrocardiogram [ECG] [EKG]511.350.0026110.17155.65238R41.0 Disorientation, unspecified411.270.002111.83391.80239R47-R49 Symptoms and signs involving speech and voice211.260.002325.33218.95243R91 Abnormal findings on diagnostic imaging of311.080.002325.33218.95	218		3	12.25	0.002	36	6.00	216.67
abnormal finding of lung fieldImage: Second	224	R70	3	11.74	0.002	15	2.50	340.00
on diagnostic imaging of other body structuresImage: second seco	225	abnormal finding of lung	4	11.73	0.002	28	4.67	242.61
involving appearance and behavior 231 R09.81 Nasal congestion 5 11.41 0.002 94 15.67 123.36 234 R94.31 Abnormal electrocardiogram [ECG] [EKG] 5 11.35 0.002 61 10.17 155.65 238 R41.0 Disorientation, unspecified 4 11.27 0.002 11 1.83 391.80 239 R47-R49 Symptoms and signs involving speech and voice 2 11.26 0.002 72 12.00 141.67 243 R91 Abnormal findings on diagnostic imaging of 3 11.08 0.002 32 5.33 218.95	226	on diagnostic imaging of	3	11.64	0.002	50	8.33	176.11
234 R94.31 Abnormal electrocardiogram [ECG] [EKG] 5 11.35 0.002 61 10.17 155.65 238 R41.0 Disorientation, unspecified 4 11.27 0.002 11 1.83 391.80 239 R47-R49 Symptoms and signs involving speech and voice 2 11.26 0.002 72 12.00 141.67 243 R91 Abnormal findings on diagnostic imaging of 3 11.08 0.002 32 5.33 218.95	228	involving appearance and	3	11.53	0.002	86	14.33	130.29
electrocardiogram [ECG] [EKG]image: second	231	R09.81 Nasal congestion	5	11.41	0.002	94	15.67	123.36
unspecifiedImage: second signs involving speech and voiceImage: second signs involving signs involving speech and voiceImage: second signs involving speech and voiceImage: second signs involving signs involving speech and voiceImage: second signs involving speech and voice <t< th=""><th>234</th><th>electrocardiogram [ECG]</th><th>5</th><th>11.35</th><th>0.002</th><th>61</th><th>10.17</th><th>155.65</th></t<>	234	electrocardiogram [ECG]	5	11.35	0.002	61	10.17	155.65
signs involving speech and voiceimage: signs involving speech and voiceimage: signs involving speech sourceimage: signs involving	238	-	4	11.27	0.002	11	1.83	391.80
on diagnostic imaging of	239	signs involving speech	2	11.26	0.002	72	12.00	141.67
lung	243	-	3	11.08	0.002	32	5.33	218.95
245 R10.9 Unspecified 4 11.05 0.002 111 18.50 110.81 abdominal pain	245	-	4	11.05	0.002	111	18.50	110.81
246R94.3 Abnormal results410.980.0026210.33151.69of cardiovascular function studies </th <th>246</th> <th>of cardiovascular</th> <th>4</th> <th>10.98</th> <th>0.002</th> <th>62</th> <th>10.33</th> <th>151.69</th>	246	of cardiovascular	4	10.98	0.002	62	10.33	151.69
251R46.8 Other symptoms410.700.0058514.17125.83and signs involving appearance and behavior	251	and signs involving	4	10.70	0.005	85	14.17	125.83
252 R20 Disturbances of skin 3 10.67 0.005 39 6.50 192.31	252	R20 Disturbances of skin sensation	3	10.67	0.005	39	6.50	192.31
sensation	253	R73.9 Hyperglycemia,	4	10.52	0.005	27	4.50	233.33

	unspecified						
266	R57 Shock, not elsewhere	3	9.92	0.008	12	2.00	350.00
200	classified						
268	R30-R39 Symptoms and signs involving the urinary system	2	9.89	0.008	162	27.00	85.19
273	R94 Abnormal results of function studies	3	9.68	0.013	125	20.83	96.83
275	R26	3	9.50	0.013	20	3.33	260.36
277	R04.0 Epistaxis	4	9.40	0.013	32	5.33	200.19
278	R59.1 Generalized enlarged lymph nodes	4	9.28	0.014	15	2.50	300.00
281	R73 Elevated blood glucose level	3	9.09	0.016	64	10.67	134.30
283	R11.2 Nausea with vomiting, unspecified	4	9.01	0.018	68	11.33	129.48
U00-	U95 Codes for special purpo	oses					
2	U00-U49 Provisional assignment of new diseases of uncertain etiology or emergency use	2	749.53	0.001	431	71.83	495.85
3	U00-U95 Codes for special purposes	1	749.53	0.001	431	71.83	495.85
5	U09 Post COVID-19 condition	3	492.73	0.001	275	45.83	500.04
6	U09.9 Post COVID-19 condition, unspecified	4	492.73	0.001	275	45.83	500.04
11	U07.1 Emergency use of U07.1 COVID-19	4	274.14	0.001	153	25.50	500.00
12	U07	3	259.86	0.001	156	26.00	488.46
	Z00-Z99 Factors influe	ncing he	eal <mark>th</mark> status a	nd cont	act with hea	lth services	
98	Z00-Z99 Factors influencing health status and contact with health services	1	25.59	0.001	1,622	270.33	41.68
115	Z69-Z76 Persons encountering health services in other circumstances	2	22.63	0.001	212	35.33	115.11
229	Z89 Acquired absence of limb	3	11.44	0.002	13	2.17	360.83

It is made available under a CC-BY-NC-ND 4.0 International license .

supplemental oxygen

It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgments

The authors gratefully acknowledge the contributions of Miranda Higginbotham.

Funding Source

This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH or other funders.

It is made available under a CC-BY-NC-ND 4.0 International license .

References:

1. RECOVER: Researching COVID to Enhance Recovery.

2. Younger DS. Post-acute sequelae of SARS-CoV-2 infection (PASC): peripheral, autonomic, and central nervous system features in a child. Neurol Sci. 2021;42(10):3959-63. doi:10.1007/s10072-021-05345-5

3. Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;4(7):e532-e41. doi:10.1016/S2589-7500(22)00048-6

4. Munipalli B, Seim L, Dawson NL, Knight D, Dabrh AMA. Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management. SN Compr Clin Med. 2022;4(1):90. doi:10.1007/s42399-022-01167-4

5. Reese J, Blau H, Bergquist T, Loomba JJ, Callahan T, Laraway B, et al. Generalizable Long COVID Subtypes: Findings from the NIH N3C and RECOVER Programs. medRxiv. 2022. doi:10.1101/2022.05.24.22275398

6. Yoo SM, Liu TC, Motwani Y, Sim MS, Viswanathan N, Samras N, et al. Factors Associated with Post-Acute Sequelae of SARS-CoV-2 (PASC) After Diagnosis of Symptomatic COVID-19 in the Inpatient and Outpatient Setting in a Diverse Cohort. J Gen Intern Med. 2022;37(8):1988-95. doi:10.1007/s11606-022-07523-3

7. Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, et al. Machine Learning for Identifying Data-Driven Subphenotypes of Incident Post-Acute SARS-CoV-2 Infection Conditions with Large Scale Electronic Health Records: Findings from the RECOVER Initiative. medRxiv. 2022. doi:10.1101/2022.05.21.22275412

8. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J Infect. 2022;84(2):158-70. doi:10.1016/j.jinf.2021.11.011

9. Palacios S, Krivchenia K, Eisner M, Young B, Ramilo O, Mejias A, et al. Long-term pulmonary sequelae in adolescents post-SARS-CoV-2 infection. Pediatr Pulmonol. 2022. doi:10.1002/ppul.26059

10. Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, Ziv A, Bar-On O, Birk E, et al. Long COVID in Children: Observations From a Designated Pediatric Clinic. Pediatr Infect Dis J. 2021;40(12):e509-e11. doi:10.1097/INF.00000000003285

11. Asadi-Pooya AA, Nemati M, Nemati H. 'Long COVID': Symptom persistence in children hospitalised for COVID-19. J Paediatr Child Health. 2022. doi:10.1111/jpc.16120

12. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, et al. Preliminary evidence on long COVID in children. Acta Paediatrica. 2021;110(7):2208-11.

13. Fainardi V, Meoli A, Chiopris G, Motta M, Skenderaj K, Grandinetti R, et al. Long COVID in Children and Adolescents. Life (Basel). 2022;12(2). doi:10.3390/life12020285

14. Roge I, Smane L, Kivite-Urtane A, Pucuka Z, Racko I, Klavina L, et al. Comparison of Persistent Symptoms After COVID-19 and Other Non-SARS-CoV-2 Infections in Children. Frontiers in Pediatrics. 2021;9. doi:10.3389/fped.2021.752385

It is made available under a CC-BY-NC-ND 4.0 International license .

15. Thallapureddy K, Thallapureddy K, Zerda E, Suresh N, Kamat D, Rajasekaran K, et al. Long-Term Complications of COVID-19 Infection in Adolescents and Children. Curr Pediatr Rep. 2022;10(1):11-7. doi:10.1007/s40124-021-00260-x

16. Morrow AK, Ng R, Vargas G, Jashar DT, Henning E, Stinson N, et al. Postacute/Long COVID in Pediatrics: Development of a Multidisciplinary Rehabilitation Clinic and Preliminary Case Series. Am J Phys Med Rehabil. 2021;100(12):1140-7.

doi:10.1097/PHM.00000000001896

17. Brackel CLH, Lap CR, Buddingh EP, van Houten MA, van der Sande L, Langereis EJ, et al. Pediatric long-COVID: An overlooked phenomenon? Pediatr Pulmonol. 2021;56(8):2495-502. doi:10.1002/ppul.25521

18. Rao S, Lee GM, Razzaghi H, Lorman V, Mejias A, Pajor NM, et al. Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program. medRxiv. 2022. doi:10.1101/2022.05.24.22275544

aapmr. CDC Announces Approval of ICD-10 Code for Post-Acute Sequelae of COVID-19.2021.

20. Mejias A, Schuchard J, Rao S, Bennett TD, Jhaveri R, Thacker D, et al. Leveraging serology testing to identify children at risk for post-acute sequelae of SARS-CoV-2 infection: An EHR-based cohort study from the RECOVER program. medRxiv. 2022:2022.06.20.22276645. doi:10.1101/2022.06.20.22276645

21. Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, et al. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. American Journal of Epidemiology. 2018;187(8):1799-807. doi:10.1093/aje/kwy049

22. Simon TD, Haaland W, Hawley K, Lambka K, Mangione-Smith R. Development and Validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 3.0. Acad Pediatr. 2018;18(5):577-80. doi:10.1016/j.acap.2018.02.010

23. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:69-80. doi:10.1002/pds.3263

24. Sun YX, Wang M, Yang MF, Zhan SY. [Review on tree-based scan statistic in drug and vaccine safety monitoring]. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42(7):1286-91. doi:10.3760/cma.j.cn112338-20201103-01297

25. Templeton AR, Maxwell T, Posada D, Stengård JH, Boerwinkle E, Sing CF. Tree scanning: a method for using haplotype trees in phenotype/genotype association studies. Genetics. 2005;169(1):441-53. doi:10.1534/genetics.104.030080

26. Kulldorff M. TreeScan User Guide, v2.0. 2020.

27. CDC. ICD-10-CM Tabular List of Diseases and Injuries. 2022.

28. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi:10.1136/bmj.n1648

29. Rando HM, Bennett TD, Byrd JB, Bramante C, Callahan TJ, Chute CG, et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv. 2021. doi:10.1101/2021.03.20.21253896

It is made available under a CC-BY-NC-ND 4.0 International license .

30. Estiri H, Strasser ZH, Brat GA, Semenov YR, Consortium for Characterization of C-bEHR, Patel CJ, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med. 2021;19(1):249. doi:10.1186/s12916-021-02115-0

31. National Institute for Health and Care Excellence: Clinical Guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE)

Copyright © NICE 2020.; 2020.

32. Asadi-Pooya AA, Nemati H, Shahisavandi M, Akbari A, Emami A, Lotfi M, et al. Long COVID in children and adolescents. World J Pediatr. 2021;17(5):495-9. doi:10.1007/s12519-021-00457-6

33. Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. European Respiratory Journal. 2022;59(2):2101341. doi:10.1183/13993003.01341-2021

34. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. JAMA. 2021. doi:10.1001/jama.2021.11880

35. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur J Pediatr. 2022;181(4):1597-607. doi:10.1007/s00431-021-04345-z

36. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021;5(10):708-18. doi:10.1016/S2352-4642(21)00198-X

37. Erol N, Alpinar A, Erol C, Sari E, Alkan K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. Cardiol Young. 2022;32(7):1085-91. doi:10.1017/s1047951121003693

38. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and metaanalyses. Sci Rep. 2022;12(1):9950. doi:10.1038/s41598-022-13495-5

39. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Longterm Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open. 2021;4(10):e2128568. doi:10.1001/jamanetworkopen.2021.28568

40. Barrett CE KA, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 20212022.

41. Naendrup JH, Garcia Borrega J, Eichenauer DA, Shimabukuro-Vornhagen A, Kochanek M, Böll B. Reactivation of EBV and CMV in Severe COVID-19-Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients. J Intensive Care Med. 2022;37(9):1152-8. doi:10.1177/08850666211053990

42. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi:10.1016/j.autrev.2021.102792